

```

chain nodes :
  13 14 21 22 30 31 32 34 41 42 43 44 50 53 54
ring nodes :
  1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20 35 36 37 38 39 40
chain bonds :
  2-54 3-53 4-13 6-14 9-13 14-30 31-32 34-37 41-42 41-43 43-44
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18
  18-19 19-20 35-36 35-40 36-37 37-38 38-39 39-40
exact/norm bonds :
  3-53 4-13 6-14 9-13 14-30 31-32 41-42 41-43 43-44
exact bonds :
  2-54 34-37 35-36 35-40 36-37 37-38 38-39 39-40
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18
  18-19 19-20
isolated ring systems :
  containing 1 : 7 : 15 : 35 :

```

G1:[*1],[*2],[*3]

G2:[*4],[*5],[*6]

G3:H,Cl,Br,F,I

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
  12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
  22:Atom 30:CLASS 31:CLASS 32:CLASS 34:CLASS 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom
  40:Atom 41:CLASS 42:CLASS 43:CLASS 44:CLASS 50:CLASS 51:Atom 53:CLASS 54:CLASS

```

Generic attributes :

```

21:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7

```

Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic
22:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic
32:
Saturation : Saturated
Number of Carbon Atoms : less than 7
44:
Saturation : Saturated
Number of Carbon Atoms : less than 7

Element Count :

Node 21: Limited

C,C5

N,N1

O,O0

S,S0

Node 22: Limited

C,C4

N,N2

O,O0

S,S0

Node 32: Limited


C,C2-4

Node 44: Limited

C,C1-3

=>

Uploading C:\Program Files\Stnexp\Queries\10568367 (RCE).str



chain nodes :

13 14 21 22 30 31 32 34 41 42 43 44 50

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20 35 36 37 38 39
40

chain bonds :

4-13 6-14 9-13 14-30 31-32 34-37 41-42 41-43 43-44

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20 35-36 35-40 36-37 37-38 38-39 39-40

```

exact/norm bonds :
4-13 6-14 9-13 14-30 31-32 41-42 41-43 43-44
exact bonds :
34-37 35-36 35-40 36-37 37-38 38-39 39-40
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 7 : 15 : 35 :

```

G1:[*1],[*2],[*3]

G2:[*4],[*5],[*6]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 30:CLASS 31:CLASS 32:CLASS 34:CLASS 35:Atom 36:Atom
37:Atom 38:Atom 39:Atom 40:Atom 41:CLASS 42:CLASS 43:CLASS 44:CLASS
50:CLASS 51:Atom

```

Generic attributes :

21:

```

Saturation      : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

```

22:

```

Saturation      : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

```

32:

```

Saturation      : Saturated
Number of Carbon Atoms : less than 7

```

44:

```

Saturation      : Saturated
Number of Carbon Atoms : less than 7

```

Element Count :

Node 21: Limited

```

C,C5
N,N1
O,O0
S,S0

```

Node 22: Limited

```

C,C4
N,N2
O,O0
S,S0

```

Node 32: Limited

```

C,C2-4

```

Node 44: Limited

```

C,C1-3

```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:53:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1160 TO ITERATE

100.0% PROCESSED 1160 ITERATIONS

43 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 21157 TO 25243

PROJECTED ANSWERS: 467 TO 1253

L2 43 SEA SSS SAM L1

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840


L3 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L4 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10568367 (RCE a).str



```

chain nodes :
13 14 21 22 30 31 32 34 41 42 43 44 50 53 54
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20 35 36 37 38 39
40
chain bonds :
2-54 3-53 4-13 6-14 9-13 14-30 31-32 34-37 41-42 41-43 43-44
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20 35-36 35-40 36-37 37-38 38-39 39-40
exact/norm bonds :

```

3-53 4-13 6-14 9-13 14-30 31-32 41-42 41-43 43-44
 exact bonds :
 2-54 34-37 35-36 35-40 36-37 37-38 38-39 39-40
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
 16-17 17-18 18-19 19-20
 isolated ring systems :
 containing 1 : 7 : 15 : 35 :

G1:[*1],[*2],[*3]

G2:[*4],[*5],[*6]

G3:H,Cl,Br,F,I

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 30:CLASS 31:CLASS 32:CLASS 34:CLASS 35:Atom 36:Atom
 37:Atom 38:Atom 39:Atom 40:Atom 41:CLASS 42:CLASS 43:CLASS 44:CLASS
 50:CLASS 51:Atom 53:CLASS 54:CLASS

Generic attributes :

21:

Saturation : Unsaturated
 Number of Carbon Atoms : less than 7
 Number of Hetero Atoms : Exactly 1
 Type of Ring System : Monocyclic

22:

Saturation : Unsaturated
 Number of Carbon Atoms : less than 7
 Number of Hetero Atoms : 2 or more
 Type of Ring System : Monocyclic

32:

Saturation : Saturated
 Number of Carbon Atoms : less than 7

44:

Saturation : Saturated
 Number of Carbon Atoms : less than 7

Element Count :

Node 21: Limited

C,C5
 N,N1
 O,O0
 S,S0

Node 22: Limited

C,C4
 N,N2
 O,O0
 S,S0

Node 32: Limited

C,C2-4

Node 44: Limited

C,C1-3

L5 STRUCTURE UPLOADED

=> que L5 AND L3 NOT L4

L6 QUE L5 AND L3 NOT L4

=> d l6

L6 HAS NO ANSWERS

L3 SCR 1840

L4 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L6 QUE L5 AND L3 NOT L4

=> s l6 sss sam

SAMPLE SEARCH INITIATED 14:58:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1090 TO ITERATE

100.0% PROCESSED 1090 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 19820 TO 23780

PROJECTED ANSWERS: 301 TO 979

L7 32 SEA SSS SAM L5 AND L3 NOT L4

=> s l6 sss ful

FULL SEARCH INITIATED 14:58:50 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 22463 TO ITERATE

100.0% PROCESSED 22463 ITERATIONS

549 ANSWERS

SEARCH TIME: 00.00.01

L8 549 SEA SSS FUL L5 AND L3 NOT L4

=> => s l8

L9 57 L8

=> d l9 1-57 bib,ab,hitstr

L9 ANSWER 1 OF 57 CAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2010:1040912 CAPLUS
 DN 153:330827
 TI Mutant ROS kinase expression in human cancers and methods and reagents for
 detection, diagnosis, and prognosis
 IN Gu, Ting-Lei; Tucker, Meghan Ann; Haack, Herbert; Crosby, Katherine
 Eleanor; Rinkunas, Victoria McGuinness
 PA Cell Signaling Technology, Inc., USA
 SO PCT Int. Appl., 126pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2010093928	A2	20100819	WO 2010-US24109	20100212
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2009-207484P P 20090212

AB The invention identifies the presence of mutant ROS protein in human cancer. Mutant ROS proteins are FIG-ROS fusion proteins comprising part of the FIG protein (a Golgi apparatus protein) fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The identification of the mutant ROS polypeptides enables new methods for determining the presence of these mutant ROS polypeptides in a biol. sample, methods for screening for compds. that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

IT 761439-42-3, NVP-TAE-684


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mutant ROS kinase expression in human cancers and methods and reagents for detection, diagnosis, and prognosis)

RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-

(CA INDEX NAME)



L9 ANSWER 2 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2010:924635 CAPLUS

DN 153:328116

TI Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

AU Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.

CS Nerviano Medical Sciences S.r.l., Nerviano (MI), 20014, Italy

SO Biochemistry (2010), 49(32), 6813-6825

CODEN: BICHAW; ISSN: 0006-2960

PB American Chemical Society

DT Journal

LA English

AB Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies. Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented. Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors. In addition, the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded β -sheet. Finally, mapping of the activating mutations associated with neuroblastoma onto the structures may explain the roles these residues have in the activation process.


IT 761439-42-3D, NVP-TAE684, complexes with anaplastic lymphoma kinase

RL: PRP (Properties)

(crystal structure; crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors)

RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-{4-(4-methyl-1-piperazinyl)-1-piperidinyl}phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-(CA INDEX NAME)



IT 761439-42-3, NVP-TAE684


RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(crystal structures of anaplastic lymphoma kinase in complex with ATP

competitive inhibitors)


RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 3 OF 57 CAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2010:725057 CAPLUS
 TI Study of the selectivity of insulin-like growth factor-1 receptor (IGF1R) inhibitors
 AU Chene, Patrick; Hau, Jean-Christophe; Blechschmidt, Anke; Fontana, Patricia; Bohn, Jacqueline; Zimmermann, Catherine; De Pover, Alain; Erdmann, Dirk
 CS Druggability-Enzymology-Profiling unit, Disease Area Oncology, Novartis Institutes of BioMedical Research, Basel, Switz.
 SO Open Enzyme Inhibition Journal (2010), 3, 27-37
 CODEN: OEIJAD; ISSN: 1874-9402
 URL: <http://www.bentham.org/open/oeij/openaccess2.htm>
 PB Bentham Science Publishers Ltd.
 DT Journal; (online computer file)
 LA English
 AB The insulin-like growth factor-1 receptor (IGF1R) is a drug target for oncol., and many studies are ongoing to identify compds. that inhibit its tyrosine kinase activity. IGF1R is highly homologous to the insulin receptor (IR) and IGF1R inhibition might be beneficial for patients, while IR inhibition may lead to limiting toxicity. Therefore selectivity for IGF1R over IR is the aim for drug design in this context. A few compds. that selectively inhibit IGF1R over IR in cells have been identified, but none of them show the same levels of selectivity in enzymic assays. To determine whether this discrepancy is linked to the conditions used in the enzymic assays, we have studied the interaction between known IGF1R inhibitors (NVP-AEW541, OSI906, AG538, NVP-TAE226) and phosphorylated/unphosphorylated IGF1R/IR proteins with both biophys. (isothermal calorimetry and surface plasmon resonance) and enzymic methods. In this report, we describe the results of this study and comment on the different degrees of selectivity IGF1R vs. IR measured in biochem. and cellular assays. Finally, our study provides new information on the biochem. and mechanism of action of these small mol. weight IGF1R inhibitors.
 IT INDEXING IN PROGRESS
 IT 761437-28-9, NVP-TAE226
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NVP-AEW541 and OSI-906 than AG 538 and NVP-TAE226 showed more selectivity for human insulin-like growth factor-1 receptor over insulin receptor)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/568,367 (RCE)

L9 ANSWER 4 OF 57 CAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2010:709884 CAPLUS
 DN 153:276861
 TI Synthesis and structure-activity relationships of
 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective
 inhibitors of the anaplastic lymphoma kinase
 AU Milkiewicz, Karen L.; Weinberg, Linda R.; Albom, Mark S.; Angeles, Thelma
 S.; Cheng, Mangeng; Ghose, Arup K.; Roemmele, Renee C.; Therooff, Jay P.;
 Underiner, Ted L.; Zificsak, Craig A.; Dorsey, Bruce D.
 CS Cephalon, Inc., West Chester, PA, 19380-4245, USA
 SO Bioorganic & Medicinal Chemistry (2010), 18(12), 4351-4362
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier B.V.
 DT Journal
 LA English
 AB Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a
 variety of cancers. A series of tetrahydropyrido[2,3-b]pyrazines was
 constructed as ring-constrained analogs of a known aminopyridine kinase
 scaffold. Chemical was developed to rapidly elaborate the SAR, structural
 elements impacting ALK inhibitory activity were exploited, and kinase
 selective analogs were identified that inhibit ALK with IC50 values
 .apprx.10 nM (enzyme) and .apprx.150 nM (cell).
 IT 761439-42-3
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation and SAR of tetrahydropyrido pyrazines as anaplastic lymphoma
 kinase inhibitors)
 RN 761439-42-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-
 piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
 (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:670328 CAPLUS
 DN 153:134474
 TI Usage of heparan sulfate, integrins, and FAK in HPV16 infection
 AU Abban, Cynthia Y.; Meneses, Patricio I.
 CS School of Graduate and Postdoctoral Studies, Rosalind Franklin University
 of Medicine and Science, North Chicago, IL, 60064, USA
 SO Virology (2010), 403(1), 1-16
 CODEN: VIRLAX; ISSN: 0042-6822
 PB Elsevier B.V.
 DT Journal
 LA English
 AB Human papillomavirus type 16 (HPV16) is the major causative agent of
 cervical cancer. Studies regarding the early binding and signaling mol.
 that play a significant role in infection are still lacking. The current
 study analyzes the role of heparan sulfate, integrins, and the signaling
 mol. FAK in HPV16 infection of human adult keratinocytes cell line
 (HaCaTs). Our data demonstrate that infection requires the binding of
 viral particles to heparan sulfate followed by activation of focal
 adhesion kinase through an integrin. Infections were reduced in the
 presence of the FAK inhibitor, TAE226. TAE226 was observed to inhibit viral
 entry to the early endosome a known infectious route. These findings
 suggest that FAK can serve as a novel target for antiviral therapy.
 IT 761437-28-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (usage of heparan sulfate, integrins, and FAK in HPV16 infection)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 6 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:641634 CAPLUS
 DN 153:27942
 TI Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits an anticancer effect in esophageal adenocarcinoma in vitro and in vivo
 AU Watanabe, Nobuyuki; Takaoka, Munenori; Sakurama, Kazufumi; Tomono, Yasuko; Hatakeyama, Shinji; Ohmori, Osamu; Motoki, Takayuki; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Haisa, Minoru; Matsuka, Junji; Beer, David G.; Nagatsuka, Hitoshi; Tanaka, Noriaki; Naomoto, Yoshio
 CS Dep. Gastroenterol. Surg., Transplant Surg. Oncol., Grad. Sch. Med., Okayama University, Okayama, 700-8558, Japan
 SO Okayama Igakkai Zasshi (2010), 122(1), 17-25
 CODEN: OIZAAV; ISSN: 0030-1558
 PB Okayama Igakkai
 DT Journal; General Review
 LA Japanese
 AB A review on roles of focal adhesion kinase (FAK) in Barrett's esophageal cancer, in vitro anticancer effect of TAE226, a dual inhibitor for FAK and IGF-1 receptor, apoptosis induction by TAE226 via AKT-BAD-caspase pathway, in vivo anticancer effect of TAE226, and possible cancer chemotherapy targeting FAK kinase.
 IT 761437-28-9
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anticancer effect of dual tyrosine kinase inhibitor for focal adhesion kinase and IGF-I receptor in esophageal adenocarcinoma in vitro and in vivo)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



L9 ANSWER 7 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:627117 CAPLUS
 DN 153:163337
 TI Thousands of chemical starting points for antimalarial lead identification
 AU Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina;
 Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren
 V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine
 E.; Cardon, Lon R.; Garcia-Bustos, Jose F.
 CS Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos,
 28760, Spain
 SO Nature (London, United Kingdom) (2010), 465(7296), 305-310
 CODEN: NATUAS; ISSN: 0028-0836
 PB Nature Publishing Group
 DT Journal
 LA English
 AB Malaria is a devastating infection caused by protozoa of the genus
 Plasmodium. Drug resistance is widespread, no new chemical class of
 antimalarials has been introduced into clin. practice since 1996 and there
 is a recent rise of parasite strains with reduced sensitivity to the
 newest drugs. We screened nearly 2 million compds. in GlaxoSmithKline's
 chemical library for inhibitors of *P. falciparum*, of which 13,533 were
 confirmed to inhibit parasite growth by at least 80% at 2 μ M concentration
 More than 8,000 also showed potent activity against the multidrug
 resistant strain Dd2. Most (82%) compds. originate from internal company
 projects and are new to the malaria community. Analyses using historic
 assay data suggest several novel mechanisms of antimalarial action, such
 as inhibition of protein kinases and host-pathogen interaction related
 targets. Chemical structures and associated data are hereby made public to
 encourage addnl. drug lead identification efforts and further research
 into this disease.
 IT 761437-28-9 1042432-58-5
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antimalarial drugs lead identification)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1042432-58-5 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




OSC.G	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT	39	THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 8 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:212373 CAPLUS
 DN 152:255168
 TI Predicting the response of tumor cells to a therapeutic agent by
 measurement of biochemical network function and the selection of cancer
 therapies
 IN Schoeberl, Birgit; Harms, Brian; Gibbons, Francis David; Fitzgerald,
 Jonathan Basil; Onsum, Matthew David; Nielsen, Ulrik; Kubasek, William
 PA Merrimack Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010019952	A2	20100218	WO 2009-US54051	20090817
	WO 2010019952	A3	20100624		
	W:		AE, AG, AL, AM, AO, AI, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA		
PRAI	US 2008-189053P	P	20080815		
	US 2008-194702P	P	20080930		
	US 2009-208206P	P	20090220		
	US 2009-170367P	P	20090417		
AB	Methods for selection of therapies for the treatment of patients by predicting the response of cells, such as tumor cells, to treatment with therapeutic agents are described. These methods involve measuring levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided. Xenografts of tumor cell lines show different responses to antibodies depending upon the level of the antigen (ErbB-3) present in the cells. Data from these cell lines were used to model the ErbB-3 pathway to predict responsiveness to these antibodies.				
IT	761437-28-9 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (predicting tumor response to; predicting response of tumor cells to therapeutic agent by measurement of biochem. network function and selection of cancer therapies)				
RN	761437-28-9 CAPLUS				

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



L9 ANSWER 9 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:192741 CAPLUS
 DN 152:469649
 TI Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase
 Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor
 Dependency
 AU McDermott, Ultan; Pusapati, Raju V.; Christensen, James G.; Gray,
 Nathanael S.; Settleman, Jeff
 CS Center for Molecular Therapeutics, Massachusetts General Hospital Cancer
 Center and Harvard Medical School, Charlestown, MA, 02129, USA
 SO Cancer Research (2010), 70(4), 1625-1634
 CODEN: CNREAS; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 AB Cancer cells harboring MET amplification display striking sensitivity to
 selective small mol. inhibitors of MET kinase, prompting their clin.
 evaluation. Similar to the experience with traditional therapeutics, most
 patients responding to treatment with such mol. targeted therapeutics
 ultimately relapse with drug-resistant disease. In this study we modeled
 acquired resistance to exptl. MET kinase inhibitor PF2341066 in
 MET-amplified non-small cell lung carcinoma (NSCLC) cell lines to identify
 drug resistance mechanisms that may arise in clinic. We found that
 activation of the epidermal growth factor receptor (EGFR) pathway emerges
 as a resistance mechanism in MET-amplified cells after prolonged exposure
 to PF2341066. Whereas combined inhibition of MET and EGFR kinases in
 MET-dependent NSCLC cells did not enhance their initial sensitivity to
 PF2341066, this combination dramatically suppressed the eventual emergence
 of drug-resistant clones after prolonged drug exposure. Conversely,
 activation of the EGFR pathway increased the yield of PF2341066-resistant
 clones, confirming the significance of this pathway in conferring
 resistance. Our findings support an intimate relationship between the
 EGFR and MET signaling pathways in NSCLC, and they suggest that
 combination treatment with MET and EGFR kinase inhibitors may be
 beneficial in MET-amplified NSCLC by reducing selection for drug resistant
 clones. Cancer Res; 70(4); 1625-34.
 IT 761439-42-3, NVP-TAE684
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (acquired resistance of non-small cell lung cancer cells to MET kinase
 inhibition is mediated by a switch to epidermal growth factor receptor
 dependency)
 RN 761439-42-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-
 piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
 (CA INDEX NAME)



OSC.G	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT	26	THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1618749 CAPLUS
 DN 152:119659
 TI Preparation of heteroaryl compounds protein kinase inhibitors
 IN Kluge, Arthur F.; Petter, Russell C.; Tester, Richland Wayne; Qiao, Lixin;
 Niu, Deqiang; Westlin, William Frederick; Singh, Juswinder; Mazdiyasni,
 Hormoz
 PA Avila Therapeutics and Uses Thereof, USA
 SO PCT Int. Appl., 560pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009158571	A1	20091230	WO 2009-US48784	20090626
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20100029610	A1	20100204	US 2009-492180	20090626
PRAI US 2008-76450P	P	20080627		
US 2009-148388P	P	20090129		
US 2009-170874P	P	20090420		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 152:119659

AB The title compds. I or II [ring A = (un)substituted Ph, 3-7 membered saturated or partially unsatd. carbocyclyl, 8-10 membered bicyclic saturated, partially unsatd. or aryl ring, etc.; ring B = (un)substituted Ph, 3-7 membered saturated or partially unsatd. carbocyclyl, 8-10 membered bicyclic saturated, partially unsatd. or aryl ring, etc.; R1 = warhead group; R2 = H, halo, CN, etc.; W1, W2 = a bond, alkylene wherein one methylene unit is optionally replaced by O, C(O), S, etc.; m, p = 0-4; R3, R4 = halo, CN, NO2, etc.], useful as inhibitors of protein kinases, were prepared E.g., a multi-step synthesis of III, starting from 2,4-dichloro-5-methylpyrimidine and 1,3-phenylenediamine, was given. Exemplified compds. I and II were tested in various biol. assays (data given for representative compds. I or II). This invention relates also to pharmaceutically acceptable compns. comprising compds. I, and methods of using the same.


IT 1202760-49-3P 1202760-53-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroaryl compds. as protein kinase inhibitors useful in treatment and prevention of kinase-mediated diseases)


RN 1202760-49-3 CAPLUS

CN Benzamide, 3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methoxy-N-methyl- (CA INDEX NAME)



RN 1202760-53-9 CAPLUS


CN Benzamide, 3-[[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methoxy-N-methyl- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 11 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1467684 CAPLUS
 DN 152:12487
 TI Preparation of phosphorus derivatives as kinase inhibitors
 IN Wang, Yihan; Huang, Wei-Sheng; Liu, Shuangying; Shakespeare, William C.;
 Thomas, R. Mathew; Qi, Jiwei; Li, Feng; Zhu, Xiaotian; Kohlmann, Anna;
 Dalgarno, David C.; Romero, Jan Antoinette C.; Zou, Dong
 PA Ariad Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 246pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009143389	A1	20091126	WO 2009-US44918	20090521
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2008-128317P	P	20080521		
	US 2008-137490P	P	20080731		
	US 2008-188796P	P	20080813		
	US 2008-192938P	P	20080923		
	US 2008-192964P	P	20080923		
OS	MARPAT 152:12487				
AB	The invention features preparation of phosphorus compds. I (X1, X3, X4 = organoamino, hydrocarbyl; ring A and E = aryl or 5- or 6-membered N, O, or sulfonyl containing heterocyclic ring; Ra, Rg = halo, cyano, alkyl, alkoxy, organoaminoxy, organoamino, hydrazino, organocarbonyl, organoamido, organosulfonyl, phosphoryl, etc.; L = O, NH2; s = 1-5; p = 1-4) and their use as kinase inhibitors. Thus, reaction of 4-aminodimethylphenylphosphine oxide with 2,4-dichloro-5-(trifluoromethyl)pyrimidine in the presence of iPr2NET in dimethylacetamide gave 4-chloro-N-[4-(dimethylphosphoryl)phenyl]-5-(trifluoromethyl)pyrimidin-2-amine which on amination with 1-methylpiperazine gave title compound, N-[4-(dimethylphosphoryl)phenyl]-4-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)pyrimidin-2-amine. The biol. activity of the compds. prepared is given.				
IT	761439-42-3	1197961-79-7	1197962-83-6		
	RL: PAC (Pharmacological activity); PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of heterocyclic amino aryl phosphorus derivs. as kinase inhibitors)				
RN	761439-42-3	CAPLUS			
CN	2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)				




RN 1197961-79-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(2-methoxyphenyl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1197962-83-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-phenyl- (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1447225 CAPLUS
 DN 152:136163
 TI Discovery of potential ZAP-70 kinase inhibitors: Pharmacophore design,
 database screening and docking studies
 AU Sanam, Ramadevi; Vadivelan, S.; Tajne, Sunita; Narasu, Lakshmi; Rambabu,
 G.; Jagarlapudi, Sarma A. R. P.
 CS Informatics Division, GVK Biosciences Pvt. Ltd., Hyderabad, Andhra
 Pradesh, 500037, India
 SO European Journal of Medicinal Chemistry (2009), 44(12), 4793-4800
 CODEN: EJMCA5; ISSN: 0223-5234
 PB Elsevier Masson SAS
 DT Journal
 LA English
 AB The best ZAP-70 inhibitor model consists of four-pharmacophore features,
 (1) one hydrogen bond acceptor, (2) one hydrogen bond donor (3) one
 hydrophobic aliphatic and (4) one hydrophobic aromatic features. This model
 was validated against 110 known ZAP-70 inhibitors with a correlation of 0.902
 as well as enrichment factor of 1.61 against a maximum value of 2. This
 model picked 4094 hits from a database of 238,819 mols. while 358 mols.
 were indicated as highly active. Subsequently, docking studies were
 performed on the hits and novel series of potent leads were suggested
 based on the interactions energy between ZAP-70 and the putative
 inhibitors which validated not only the virtual screening potential of the
 model but also identified the possible new Chemotypes.
 IT 761437-30-3 761437-86-9 761438-93-1
 761438-98-6 761438-99-7 761439-44-5
 761439-57-0
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (pharmacophore design, database screening and docking studies of
 potential ZAP-70 kinase inhibitors)
 RN 761437-30-3 CAPLUS
 CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-
 [(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-
 (CA INDEX NAME)




RN 761437-86-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-
 pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 761438-93-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-98-6 CAPLUS

CN 1-Propanone, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazine-2-methyl- (CA INDEX NAME)




RN 761438-99-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N-methyl- (CA INDEX NAME)




RN 761439-44-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-nitrophenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-57-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(methylanino)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:1258865 CAPLUS

DN 151:448447

TI Preparation of pyrimidine derivatives as protein kinase inhibitors for treating proliferative disorders, immune disorders, and infections

IN Chen, Bei; Jiang, Tao; Marsilje, Thomas H.; Michellys, Pierre-Yves; Nguyen, Truc Ngoc; Pei, Wei; Wu, Baogen; Gao, Zhaobo; Ge, Yonghui; Huang, Chen; Li, Yuncheng

PA IRM LLC, Bermuda; Novartis A.-G.

SO PCT Int. Appl., 149pp.

CODEN: P1XXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009126515	A1	20091015	WO 2009-US39383	20090403
	W:	AE, AG, AL, AM, AN, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2008-43111P	P	20080407		
	US 2008-116023P	P	20081119		
OS	MARPAT 151:448447				

AB The invention relates to pyrimidine derivs. having Formula I or II (wherein R1 and R2 are H, C1-6 alkyl or halo-substituted C1-6 alkyl; R3 is halo, C1-6 alkyl, or a halo-substituted C1-6 alkyl; R4 is H; alternatively, R3 and R4 together form part of a ring; R5, R6 and R8 are independently C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl or C2-6 alkynyl, each optionally substituted; R7 is sulfamoyl, carbamoyl, etc.; R9 is -L-S(O)2R18, -L-S(O)2NRR17, etc.; R is H or C1-6alkyl; R17 and R18 are independently C1-6 alkyl, halo-substituted C1-6 alkyl, etc.; L is (CR2)1-4 or a bond; n = 1-2) and methods for using such compds. as kinase inhibitors for disease treatment. For example, the compds. of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) kinase activity or a combination thereof. Synthetic procedures for preparing the pyrimidines of the invention are claimed as are compns. containing them. Example compound III, prepared in a multistep synthesis

that culminated in the reaction of corresponding piperidine intermediate with dimethylamino acetyl halide, had an IC50 of 0.026 μ M in an ALK assay.

IT 1190399-47-3P 1190399-50-8P 1190400-18-0P
 , 1-[4-[4-[[5-Chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-yl]amino]-5-methoxy-2-methylphenyl]piperidin-1-yl]-2-(dimethylamino)ethanone 1190400-20-4P 1190400-21-5P
 , (R)-3-[4-[4-[[5-Chloro-4-[[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-


yl]amino]-5-isopropoxy-2-methylphenyl]piperidin-1-yl]-1,1,1-trifluoropropan-2-ol 1190400-24-8P,
(S)-3-[4-[4-[5-chloro-4-[2-(isopropylsulfonyl)phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidin-1-yl]-1,1,1-trifluoropropan-2-ol

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as protein kinase inhibitors for treating proliferative disorders, immune disorders, and infections)

RN 1190399-47-3 CAPLUS


CN Ethanone, 1-[4-[4-[5-chloro-4-[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 1190399-50-8 CAPLUS


CN Methanone, [4-[4-[5-chloro-4-[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]-1-piperidinyl]-2-(2-pyrrolidinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1190400-18-0 CAPLUS

CN Ethanone, 1-[4-[4-[5-chloro-4-[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5-methoxy-2-methylphenyl]-1-piperidinyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 1190400-20-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)



RN 1190400-21-5 CAPLUS

CN 1-Piperidineethanol, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]-α-(trifluoromethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1190400-24-8 CAPLUS

CN 1-Piperidineethanol, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-

methylethoxy)phenyl]- α -(trifluoromethyl)-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 1032903-64-2P, 4-[4-[[5-Chloro-4-[[2-[(propan-2-yl)sulfonyl]phenyl]amino]pyrimidin-2-yl]amino]-5-isopropoxy-2-methylphenyl]piperidine-1-carboxylic acid tert-butyl ester
1190399-48-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as protein kinase inhibitors for treating proliferative disorders, immune disorders, and infections)


RN 1032903-64-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1190399-48-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1201246 CAPLUS
 DN 151:418110
 TI Methods of chemotype evolution
 IN Hansen, Stig; Erlanson, Dan; Cancilla, Mark
 PA Sunesis Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 106pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009120795	A1	20091001	WO 2009-US38276	20090325
W:	AE, AG, AL, AM, AO, AT, AU , AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2008-39422P	P	20080325		
US 2008-45265P	P	20080415		
US 2008-48545P	P	20080428		


AB Herein is described a method to rapidly screen a large chemical space for a compound that binds to a target protein through an iterative fragment assembly approach that can be performed at low reagent cost and without requiring purification of the assembled product. The method employs a library of test ligands each of which comprise a 'bait' mol., which is known from prior art or prior screening to have some intrinsic affinity for the target protein, and a test moiety.

IT 761439-42-3

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (methods of chemotype evolution)

RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
 (CA INDEX NAME)



10/568,367 (RCE)

L9 ANSWER 15 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1130268 CAPLUS
 DN 151:381385
 TI Preparation of 5-fluoro-4N-phenyl-4-pyrimidinamine compounds and their use
 as inhibitors of IgE and/or IgG receptor signaling cascades
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald; Molineaux, Susan; Holland,
 Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Sylvain,
 Catherine; Li, Hui; Rossi, Alexander B.
 PA Rigel Pharmaceuticals, Inc., USA
 SO U.S., 259pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7589200	B2	20090915	US 2004-911684	20040803
	US 20050209230	A1	20050922		
	US 20040029902	A1	20040212	US 2003-355543	20030131
	US 7557210	B2	20090707		
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	US 20050038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	ZA 2004005979	A	20070425	ZA 2004-5979	20040727
	US 20060025410	A1	20060202	US 2005-149105	20050608
	US 7329672	B2	20080212		
	US 20060035916	A1	20060216	US 2005-148746	20050608
	US 7329671	B2	20080212		
	US 20060058292	A1	20060316	US 2005-149418	20050608
	US 7332484	B2	20080219		
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	US 20070225321	A1	20070927	US 2006-539013	20061005
	US 20070293520	A1	20071220	US 2006-539018	20061005
	US 7498435	B2	20090303		
	US 20070293521	A1	20071220	US 2006-539029	20061005
	US 7642351	B2	20100105		
	US 20070293522	A1	20071220	US 2006-539041	20061005
	US 20070293523	A1	20071220	US 2006-539049	20061005
	US 20070293524	A1	20071220	US 2006-539054	20061005
	US 7485724	B2	20090203		
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		
	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 7655797	B2	20100202		
	US 20090171085	A1	20090702	US 2008-268235	20081110
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
	US 20090171086	A1	20090702	US 2009-363537	20090130
	US 20100197918	A1	20100805	US 2010-762178	20100416
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	AU 2003-208931	A3	20030131		
	US 2004-858343	A3	20040601		

US 2005-149418	A1	20050608
US 2006-539041	A1	20061005
US 2006-539049	A1	20061005
US 2006-539054	A3	20061005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 151:381385

AB The invention provides 2,4-pyrimidinediamine compds. of formula I that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; intermediates and methods of synthesizing the compds. and methods of using the compds. in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation

and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Compds. of formula I wherein R4 is substituted phenyl; LG is a leaving group; and salts, hydrates, solvates, N-oxides and prodrugs thereof, are claimed. Example compound II was prepared by nucleophilic aromatic substitution reaction of 2,4-dichloropyrimidine with 4-ethoxyaniline. All the invention compds. were evaluated for their inhibitory activity fo IgE and/or IgG receptor signaling cascades (some data given).


IT 575484-59-2P 575484-65-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-phenyl(fluoro)pyrimidinamine compds. as IgE and/or IgG receptor signaling cascade inhibitors useful in the treatment of diseases)


RN 575484-59-2 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)



RN 575484-65-0 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-(1-methylethyl)- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
 RE.CNT 361 THERE ARE 361 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:1120609 CAPLUS

DN 152:281447

TI 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226

AU Hehlhans, Stephanie; Lange, Inga; Eke, Iris; Cordes, Nils

CS OncoRay - Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, 01307, Germany

SO Radiotherapy and Oncology (2009), 92(3), 371-378

CODEN: RAONDT; ISSN: 0167-8140

PB Elsevier Ireland Ltd.

DT Journal

LA English

AB Background and purpose: Focal adhesion kinase (FAK), a main player in integrin signaling and survival, is frequently overexpressed in human cancers and therefore postulated as potential target in cancer therapy. The aim of this study was to evaluate the radiosensitizing potential of the FAK inhibitor TAE226 in three-dimensional (3D) tumor cell cultures. Materials and methods: Head and neck squamous cell carcinoma (HNSCC) cells (FaDu, UT-SCC15, UT-SCC45), lung cancer cells (A549), colorectal carcinoma cells (DLD-1, HCT-116) and pancreatic tumor cells (MiaPaCa2, Panc1) were treated with different concns. of TAE226 (0-1 μ M; 1 or 24 h) without or in combination with irradiation (0-6 Gy, X-ray, single dose). Subsequently, 3D clonogenic survival assays (laminin-rich extracellular matrix) and Western blotting (expression/phosphorylation, e.g. FAK, Akt, ERK1/2) were performed. Results: All investigated 3D cell cultures showed a dose-dependent reduction in clonogenic survival by TAE226. Intriguingly, TAE226 only significantly radiosensitized 3D HNSCC cell cultures accompanied by a pronounced dephosphorylation of FAK, Akt and ERK1/2. Conclusions: Our data demonstrate TAE226 as potent FAK inhibitor that enhances the cellular radiosensitivity particularly of HNSCC cells grown in a 3D cell culture model. Future in vitro and in vivo investigations will clarify, to which extent this approach might be clin. relevant for radiotherapy of HNSCC.


IT 761437-28-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by focal adhesion kinase inhibitor TAE226)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/568,367 (RCE)

L9 ANSWER 17 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1018691 CAPLUS
 DN 151:280946
 TI FISH assay for echinoderm microtubule-associated protein-like 4 (EML4) and
 IN anaplastic lymphoma kinase (ALK) gene chromosomal inversion in lung cancer
 PA Lee, Charles; Murphy, Carly; Janne, Pasi
 SO The Brigham and Women's Hospital, Inc., USA; Dana-Farber Cancer Institute
 PCT Int. Appl., 64pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009102446	A2	20090820	WO 2009-US879	20090212
	WO 2009102446	A3	20091126		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2008-65422P P 20080212

AB Described herein are methods and compns. for performing a FISH assay for the detection of a chromosomal inversion involving EML4 and ALK. Also included are methods for diagnosing and prognosing non-small cell lung cancer (NSCLC) based at least in part on a fluorescent in situ hybridization (FISH) assay to detect an EML4-ALK chromosomal inversion, and methods for treating diseases characterized by expression of an EML4-ALK inversion using compns. that inhibit ALK kinase activity. The invention relates, at least in part, to the discovery that a fluorescent in situ hybridization assay (FISH) can be used to detect a chromosomal inversion that results in an EML4-ALK inversion. The prevalence of this chromosomal inversion in non-small cell lung cancer (NSCLC) leads to diagnostic and prognostic applications for the FISH assay described herein. Use of the FISH assay for detection of an EML4-ALK inversion also has applications for determining appropriate treatment strategies for subjects who exhibit such a gene fusion. Further described herein are probes for use in a FISH assay for detecting an EML4-ALK inversion, methods for generating such probes, and kits containing such probes. The frequency of the EML4-ALK inversion in NSCLC cell lines and primary tumors from NSCLC patients of different ethnic backgrounds was characterized. EML4-ALK was detected in 3 NSCLC cell lines including one established (DFCI032) from a previously untreated female never smoker with lung adenocarcinoma. One of the three cell lines with the EML4-ALK translocation (H3122) was also found to be exquisitely sensitive and undergo significant apoptosis following treatment with an ALK kinase inhibitor (NVP-TAE684).


IT 761439-42-3, NVP-TAE684

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (FISH assay for echinoderm microtubule-associated protein-like 4 (EML4))

and anaplastic lymphoma kinase (ALK) gene chromosomal inversion in lung cancer)


RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)




L9 ANSWER 18 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1015029 CAPLUS
 DN 151:280249
 TI Treatment of acne vulgaris, rosacea and rhinophym with inhibitors of the
 fibroblast growth factor receptor 2 and insulin-like growth factor 1
 receptor signal pathways
 IN Melnik, Bodo
 PA Germany
 SO PCT Int. Appl., 39pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009101199	A2	20090820	WO 2009-EP51749	20090216
WO 2009101199	A3	20091126		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI EP 2008-101654	A	20080215		
EP 2008-154022	A	20080403		
US 2008-123294P	P	20080407		
EP 2008-164431	A	20080916		
EP 2008-168765	A	20081110		
AB	A composition for the treatment of acne vulgaris, rosacea and/or rhinophym comprises at least one inhibitor of the FGFR2 signal pathway and/or IGF1R signal pathway. Also claimed is a bovine milk or a product of bovine milk having a reduced content of hormones, especially progesterone and growth factors, like IGF-1 and IGF-2, FGF1, and FGF2, or having a modified casein which has a reduced influence on IGF-1 levels. Further, use of Metformin for the prevention of adenocarcinomas, cardiovascular diseases and neurodegenerative diseases, is also presented.			
IT	761437-28-9 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (as inhibitor of IGF1R tyrosine kinase, as inhibitor of IGF-1 receptor signal pathway; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)			
RN	761437-28-9 CAPLUS			
CN	Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)			




L9 ANSWER 19 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:514975 CAPLUS
 DN 151:520
 TI A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually
 High Selectivity against Aurora B
 AU Aliagas-Martin, Ignacio; Burdick, Dan; Corson, Laura; Dotson, Jennafer;
 Drummond, Jason; Fields, Carter; Huang, Oscar W.; Hunsaker, Thomas;
 Kleinheinz, Tracy; Krueger, Elaine; Liang, Jun; Moffat, John; Phillips,
 Gail; Pulk, Rebecca; Rawson, Thomas E.; Ultsch, Mark; Walker, Leslie;
 Wiesmann, Christian; Zhang, Birong; Zhu, Bing-Yan; Cochran, Andrea G.
 CS Departments of Small Molecule Drug Discovery, Cell Regulation,
 Translational Oncology and Protein Engineering, Genentech Inc., South San
 Francisco, CA, 94080, USA
 SO Journal of Medicinal Chemistry (2009), 52(10), 3300-3307
 CODEN: JMCMAR; ISSN: 0022-2625
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 151:520
 AB The two major Aurora kinases carry out critical functions at distinct mitotic
 stages. Selective inhibitors of these kinases, as well as pan-Aurora
 inhibitors, show antitumor efficacy and are now under clin. investigation.
 However, the ATP-binding sites of Aurora A and Aurora B are virtually
 identical, and the structural basis for selective inhibition has therefore
 not been clear. We report here a class of bisanilinopyrimidine Aurora A
 inhibitors with excellent selectivity for Aurora A over Aurora B, both in
 enzymic assays and in cellular phenotypic assays. Crystal structures of
 two of the inhibitors in complex with Aurora A implicate a single amino
 acid difference in Aurora B as responsible for poor inhibitory activity
 against this enzyme. Mutation of this residue in Aurora B (E161T) or
 Aurora A (T217E) is sufficient to swap the inhibition profile, suggesting
 that this difference might be exploited more generally to achieve high
 selectivity for Aurora A.
 IT 1158838-71-1 1158838-73-3 1158838-74-4
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bisanilinopyrimidine Aurora A inhibitors with high selectivity)
 RN 1158838-71-1 CAPLUS
 CN Benzamide, 4-[[5-fluoro-2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]amino]-
 N,N-dimethyl- (CA INDEX NAME)




RN 1158838-73-3 CAPLUS

CN Benzamide, 4-[[5-fluoro-2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)



RN 1158838-74-4 CAPLUS

CN Benzamide, 4-[[5-fluoro-2-[(4-hydroxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:448699 CAPLUS
 DN 150:423212
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor
 modulators for treatment of autoimmune diseases
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim,
 Holger; Bhamidipati, Somasekhar; Sylvain, Catherine; Li, Hui
 PA Rigel Pharmaceuticals, Inc., USA
 SO U.S., 300pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7517886	B2	20090414	US 2003-631029	20030729
	US 20070060603	A1	20070315		
	CA 2492325	A1	20040219	CA 2003-2492325	20030729
	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003265336	A1	20040225	AU 2003-265336	20030729
	AU 2003265336	B2	20080619		
	EP 1534286	A1	20050601	EP 2003-784871	20030729
	EP 1534286	B1	20091209		
	R: AT, BE, BG, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013059	A	20050705	BR 2003-13059	20030729
	CN 1678321	A	20051005	CN 2003-821120	20030729
	JP 2006514989	T	20060518	JP 2005-506142	20030729
	NZ 537752	A	20061222	NZ 2003-537752	20030729
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	CN 101514191	A	20090826	CN 2009-10006771	20030729
	EP 2130541	A2	20091209	EP 2009-4539	20030729
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
	AT 451104	T	20091215	AT 2003-784871	20030729
	RU 2376992	C2	20091227	RU 2005-105344	20030729
	ES 2337782	T3	20100429	ES 2003-784871	20030729
	HR 2005000089	A2	20070831	HR 2005-89	20050126
	SE 2005000203	A	20050329	SE 2005-203	20050127
	NO 2005001069	A	20050228	NO 2005-1069	20050228
	IN 2005KN00302	A	20060421	IN 2005-KN302	20050228
	HK 1079978	A1	20100723	HK 2005-110991	20051201
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	US 20070299095	A1	20071227	US 2006-539101	20061005
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		

	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 7655797	B2	20100202		
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
	US 20100125069	A1	20100520	US 2010-691657	20100121
	US 20100197918	A1	20100805	US 2010-762178	20100416
PRAI	US 2002-399673P	P	20020729		
	US 2003-443949P	P	20030131		
	US 2003-452339P	P	20030306		
	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-434277P	P	20021217		
	AU 2003-208931	A3	20030131		
	US 2003-355543	A1	20030131		
	CN 2003-821120	A3	20030729		
	EP 2003-784871	A3	20030729		
	US 2003-631029	A	20030729		
	WO 2003-US24087	W	20030729		
	US 2004-858343	A3	20040601		
	US 2005-149418	A1	20050608		
	US 2006-539041	A1	20061005		
	US 2006-539049	A1	20061005		
	US 2006-539054	A3	20061005		
	US 2006-539101	A1	20061005		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB Title compds. I [wherein L1 and L2 = independently a bond; R2, R4 = independently (un)substituted Ph, 5-15 membered heteroaryl; ; R5 = CN, NC, NO2, F, (per)haloalkyl, (per)haloalkoxy, COCF3, etc.; R6 = H; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).

IT 575484-59-2P 575484-65-0P 662227-39-6P
662227-46-5P 662227-55-6P 662227-67-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)


RN 575484-59-2 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)




RN 575484-65-0 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-(1-methylethyl)- (CA INDEX NAME)




RN 662227-39-6 CAPLUS

CN Benzamide, N-(2-aminoethyl)-5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 662227-46-5 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 662227-55-6 CAPLUS


CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylamino)ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 662227-67-0 CAPLUS

CN Benzamide, N-[(2R)-2,3-dihydroxypropyl]-5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 277 THERE ARE 277 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:293033 CAPLUS
 DN 150:306669
 TI Pyrimidine derivatives as IGF-1R and ALK inhibitors and their preparation,
 pharmaceutical compositions and use in the treatment of diseases
 IN Marsilje, Thomas H.; Lu, Wenshuo; Chen, Bei; He, Xiaohui; Bursulaya,
 Badry; Lee, Christian Cho-Hua; Gray, Nathanael S.
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009032668	A2	20090312	WO 2008-US74392	20080827
	WO 2009032668	A3	20090924		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2008296545	A1	20090312	AU 2008-296545	20080827
	CA 2696824	A1	20090312	CA 2008-2696824	20080827
	KR 2010050557	A	20100513	KR 2010-706599	20080827
	EP 2190826	A2	20100602	EP 2008-798753	20080827
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
	MX 2010002336	A	20100325	MX 2010-2336	20100226
	IN 2010DN01657	A	20100806	IN 2010-DN1657	20100310
PRAI	US 2007-966449P	P	20070828		
	US 2008-75556P	P	20080625		
	WO 2008-US74392	W	20080827		

OS MARPAT 150:306669


AB The invention provides pyrimidine derivs. of formula I and their pharmaceutical compns. thereof, and methods for using such compds. Pyrimidine derivs. of formula I may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK). Compds. of formula I wherein R1a is H, halo, OR8, NRR8, SR8, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, C2-6 alkenyl, (un)substituted C2-6 alkynyl, etc.; R1b is H and NH2; R3 and R4 are independently H, COR7 and (halo)C1-6 alkyl; each of R5-R7 is independently (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, halo, NO2, CN, OR8, etc.; two adjacent R5 may taken together with the carbon atom attached to form (un)substituted 9- to 14-membered ring; R7-R9 are independently (CR2)0-4-Y, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, (un)substituted C2-6 alkenyl and (un)substituted C2-6 alkynyl; R7 and R8 may be H; R is H and C1-6 alkyl; Y

is (un)substituted C3-12 (hetero)cyclic ring, (un)substituted C6-10 aryl, (un)substituted C5-10 heteroaryl and heterocyclic ring; m is 1-4; n is 0-4; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by N-arylation of 4'-amino-5'-fluoro-N,2'-dimethylbiphenyl-4-carboxamide with 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine. All the invention compds. were evaluated for their kinase inhibitory activity. From the assay, it was determined that some of the tested compds. exhibited the IC50 value of < 1 nM.


- IT 1129409-71-7P 1129409-73-9P 1129409-74-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrimidine derivs. as IGF-1R and ALK inhibitors useful in treatment of diseases)
 RN 1129409-71-7 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[[5-chloro-4-[[2-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-fluoro-N,2'-dimethyl- (CA INDEX NAME)



- RN 1129409-73-9 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[[4-[[2-[[[2-aminoethyl]amino]carbonyl]phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5'-fluoro-N,2'-dimethyl- (CA INDEX NAME)




- RN 1129409-74-0 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[[5-chloro-4-[[2-[[[2-(hydroxyethyl)amino]carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-fluoro-N,2'-dimethyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L9 ANSWER 22 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:277182 CAPLUS
 DN 150:413026
 TI SVM Model for Virtual Screening of Lck Inhibitors
 AU Liew, Chin Y.; Ma, Xiao H.; Liu, Xianghui; Yap, Chun W.
 CS Pharmaceutical Data Exploration Laboratory, Department of Pharmacy,
 National University of Singapore, Singapore
 SO Journal of Chemical Information and Modeling (2009), 49(4), 877-885
 CODEN: JCISD8; ISSN: 1549-9596
 PB American Chemical Society
 DT Journal
 LA English
 AB Lymphocyte-specific protein tyrosine kinase (Lck) inhibitors have
 treatment potential for autoimmune diseases and transplant rejection. A
 support vector machine (SVM) model trained with 820 pos. compds. (Lck
 inhibitors) and 70 neg. compds. (Lck noninhibitors) combined with 65 142
 generated putative negatives was developed for predicting compds. with a
 Lck inhibitory activity of $IC_{50} \leq 10 \mu M$. The SVM model, with an
 estimated sensitivity of greater than 83% and specificity of greater than 99%,
 was used to screen 168 014 compds. in the MDDR and was found to have a
 yield of 45.8% and a false pos. rate of 0.52%. The model was also able to
 identify novel Lck inhibitors and distinguish inhibitors from structurally
 similar noninhibitors at a false pos. rate of 0.27%. To the best of our
 knowledge, the SVM model developed in this work is the first model with a
 broad applicability domain and low false pos. rate, which makes it very
 suitable for the virtual screening of chemical libraries for Lck inhibitors.
 IT 944795-19-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (SVM model for virtual screening of Lck inhibitors)
 RN 944795-19-1 CAPLUS
 CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-
 N,N,4-trimethyl- (CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:39051 CAPLUS

DN 150:89997

TI Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor

AU Sakurama, Kazufumi; Noma, Kazuhiro; Takaoka, Munenori; Tomono, Yasuko; Watanabe, Nobuyuki; Hatakeyama, Shinji; Ohmori, Osamu; Hirota, Seichi; Motoki, Takayuki; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Haisa, Minoru; Matsuoka, Junji; Tanaka, Noriaki; Naomoto, Yoshio

CS Department of Gastroenterological Surgery, Transplant, and Surgical Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, 700-9558, Japan

SO Molecular Cancer Therapeutics (2009), 8(1), 127-134
CODEN: MCTOCF; ISSN: 1535-7163

PB American Association for Cancer Research

DT Journal

LA English


AB Focal adhesion kinase (FAK) is often up-regulated in a variety of malignancies, including gastrointestinal stromal tumor (GIST), and its overexpression seems to be associated with tumor aggressiveness and poor prognosis. GIST is well known to have a mutation to c-KIT; thus, a specific c-KIT inhibitor (imatinib) is recognized as the first-line chemotherapy for GIST, although a certain type of c-KIT mutation reveals a resistance to imatinib due to as yet uncertain mol. mechanisms. To assess the c-KIT mutation-related variation of cellular responses to imatinib, murine lymphocyte-derived Ba/F3 cells, which are stably transduced with different types of c-KIT mutation, were treated with either imatinib or a FAK inhibitor (TAE226), and their antitumor effects were determined in vitro and in vivo. A mutation at exon 11 (KITdel559-560) displayed a high sensitivity to imatinib, whereas that at exon 17 (KIT820Tyr) showed a significant resistance to imatinib in vitro and in vivo. KIT820Tyr cells appeared to maintain the activities of FAK and AKT under the imatinib treatment, suggesting that FAK might play a role in cell survival in imatinib-resistant cells. When FAK activity in those cells was inhibited by TAE226, cell growth was equally suppressed and the cells underwent apoptosis regardless of the c-KIT mutation types. Oral administration of TAE226 significantly diminished tumor growth in nude mice bearing KIT820Tyr xenografts. In summary, c-KIT mutation at exon 17 displayed a resistance to imatinib with maintained activations of FAK and subsequent survival signals. Targeting FAK could be a potential therapeutic strategy for imatinib-resistant GISTs.

IT 761437-28-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of focal adhesion kinase with TAE226 as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor)


RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




OSC.G	11	THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
RE.CNT	46	THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 24 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:36532 CAPLUS
 DN 150:555130
 TI TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on
 mTOR signaling in esophageal cancer cells
 AU Wang, Zhi Gang; Fukazawa, Takuya; Nishikawa, Toshio; Watanabe, Nobuyuki;
 Sakurama, Kazufumi; Motoki, Takayuki; Takaoka, Munenori; Hatakeyama,
 Shinji; Omori, Osamu; Ohara, Toshiaki; Tanabe, Shunsuke; Fujiwara,
 Yasuhiro; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Tanaka, Noriaki;
 Naomoto, Yoshio
 CS College of Life Science, The Key Laboratory of Mammal Reproductive Biology
 and Biotechnology, Ministry of Education, Inner Mongolia University,
 Huhhot, 010021, Peop. Rep. China
 SO Oncology Reports (2008), 20(6), 1473-1477
 CODEN: OCRPEW; ISSN: 1021-335X
 PB Oncology Reports
 DT Journal
 LA English
 AB Esophageal cancer is one of the most aggressive cancers in the world.
 Novel preventive and therapeutic strategies tend to target the key mols.
 involved in the signaling transduction pathways for cell growth. It is
 known that FAK and mTOR are important controllers of cell growth. TAE226,
 a novel small mol. compound, is a potent ATP competitive inhibitor of FAK
 and IGF-IR. TAE226 can block FAK and IGF-IR signaling pathways. The
 purpose of this study was to explore the inhibitory effects on mTOR
 signaling and the mechanism of cell growth suppression by TAE226. We
 examined the expression of mTOR and S6 in esophageal cancer cells (SEG-1)
 and normal esophageal epithelial cells (KOB-13) and the efficacy of TAE226
 against SEG-1 cells. mTOR and S6 were overexpressed in SEG-1 cells
 compared with KOB-13 cells. TAE226 inhibited the expression of mTOR, Akt,
 p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt
 (Ser473), p70S6K (Thr389) and S6 (Ser240/244). As a result, TAE226
 induced a dose-dependent decrease in cell growth (number) and damage in the
 cell shape. Together, these data show that TAE226 has potent inhibitory
 effects on mTOR signaling and esophageal cancer cell growth indicating
 that TAE226 has potential application in esophageal cancer treatment.
 IT 761437-28-9
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TAE226, dual inhibitor for FAK and IGF-IR, has inhibitory effects on
 mTOR signaling in esophageal cancer cells)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT	29	THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 25 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1477507 CAPLUS
 DN 151:26548
 TI Crystal structures of the FAK kinase in complex with TAE 226 and related
 bis-anilino pyrimidine inhibitors reveal a helical DFG conformation
 AU Lietha, Daniel; Eck, Michael J.
 CS Department of Biological Chemistry and Molecular Pharmacology, Harvard
 Medical School, Boston, MA, USA
 SO PLoS One (2008), 3(11), No pp. given
 CODEN: PLOINCL; ISSN: 1932-6203
 URL: <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0003800>
 PB Public Library of Science
 DT Journal; (online computer file)
 LA English
 AB Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase required for cell migration, proliferation and survival. FAK overexpression has been documented in diverse human cancers and is associated with a poor clinical outcome. Recently, a novel bis-anilino pyrimidine inhibitor, TAE 226, was reported to efficiently inhibit FAK signaling, arrest tumor growth and invasion, and prolong the life of mice with glioma or ovarian tumor implants. Here, the authors describe the crystal structures of FAK kinase bound to TAE 226 and to 3 related bis-anilino pyrimidine compounds. TAE 226 induced a conformation of the N-terminal portion of the kinase activation loop that was only observed in FAK, but was distinct from the conformation in both the active and inactive states of the kinase. This conformation appeared to require a Gly residue immediately N-terminal to the "DFG motif", which adopted a helical conformation stabilized by interactions with TAE 226. The presence of a Gly residue in this position contributed to the specificity of TAE 226 and related compounds for FAK. This work highlights the fact that kinases can access conformational space that is not necessarily utilized for their native catalytic regulation, and that such conformations can explain and be exploited for inhibitor specificity.
 IT 761437-28-9D, complexes with FAK kinase
 RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PEP (Physical, engineering or chemical process); PRP (Properties); BIOL (Biological study); PROC (Process)
 (crystal structures of FAK kinase in complex with TAE 226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

10/568,367 (RCE)

L9 ANSWER 26 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1450755 CAPLUS
 DN 150:20148
 TI Preparation of substituted 2-[(3-pyridylamino)-2-pyrimidinyl]anthranilamides as Aurora kinase inhibitors
 IN Axten, Jeffrey Michael; Betancourt, Jesus R. Medina; Johnson, Neil W.; Semones, Marcus
 PA SmithKline Beecham Corporation, USA
 SO PCT Int. Appl., 55pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008147831	A1	20081204	WO 2008-US64446	20080522
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2007-939624P	P	20070523		
OS	CASREACT 150:20148; MARPAT 150:20148				
AB	Title compds. I (R1 = H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkylmethyl, C1-6 hydroxyalkyl; R2 = Me, F, Cl; R3 = nitrogen-containing 5- or 6-membered heterocycle), or pharmaceutically acceptable salts thereof, are prepared as Aurora kinase inhibitors. Thus, reaction of 2,4-dibromo-5-methylpyrimidine with 2-amino-N-isopropylbenzamide, followed by further reaction with 6-(4-methyl-2-piperazinyl)-3-pyridinamine gave title compd II, isolated as the HCl salt. The prepared compds. were tested for Aurora A/TPX12 and Aurora B/INCENP protein kinase inhibitory activities in substrate phosphorylation assays (no data).				
IT	1089653-50-8P	1089653-62-2P	1089653-63-3P		
	1089653-64-4P	1089653-68-8P	1089653-71-3P		
	1089653-72-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of substituted 2-[(3-pyridylamino)-2-pyrimidinyl]anthranilamides as Aurora kinase inhibitors)				
RN	1089653-50-8	CAPLUS			
CN	Benzamide, 2-[[5-fluoro-2-[[6-(4-methyl-1-piperazinyl)-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)				



● HCl


RN 1089653-62-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[6-(4-methyl-1-piperazinyl)-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1089653-63-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[6-(4-morpholinyl)-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1089653-64-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[1,6-dihydro-6-oxo-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1089653-68-8 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-(4-methyl-1-piperazinyl)-5-pyrimidinyl]amino]-4-pyrimidinyl]amino]-N-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 1089653-67-7
 CMF C21 H24 Cl N9 O




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 1089653-71-3 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[5-methyl-6-(4-methyl-1-piperazinyl)-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, hydrochloride

(1:1) (CA INDEX NAME)




● HCl

RN 1089653-72-4 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[[6-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-5-methyl-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 27 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:1360637 CAPLUS

DN 149:553338

TI Genetic polymorphisms associated with an increased risk of neurodegenerative disease and their detection and diagnostic and prophylactic use

IN Grupe, Andrew; Li, Yonghong

PA Applera Corporation, USA

SO PCT Int. Appl., 137pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008137110	A1	20081113	WO 2008-US5734	20080501
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20080286796 A1 20081120 US 2008-151163 20080501 PRAI US 2007-927864P P 20070503				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The present invention is based on the discovery of genetic polymorphisms that are associated with neurodegenerative disease, particularly Alzheimer's disease and Parkinson's disease. In particular, the present invention relates to nucleic acid mols. containing the polymorphisms, variant proteins encoded by such nucleic acid mols., reagents for detecting the polymorphic nucleic acid mols. and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. An anal. of genetic polymorphisms surrounding the NEDD9 gene is reported. Expression of the NEDD9 gene is lower in the hippocampus of Alzheimer's disease patients than in controls. A number of polymorphisms around the gene were shown to be associated with an increased risk of Alzheimer's disease.

IT 761437-28-9, NVP-TAE-226

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (in treatment of Alzheimer's disease; genetic polymorphisms associated with increased risk of neurodegenerative disease and their detection and diagnostic and prophylactic use)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 28 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:1009042 CAPLUS

DN 149:293683

TI Combinations of therapeutic agents comprising

N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide for treating cancer

IN Atadja, Peter Wisdom; Shao, Wenlin; Bhalla, Kapil N.

PA Novartis A.-G., Switz.

SO PCT Int. Appl., 73pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008100985	A2	20080821	WO 2008-US53798	20080213
WO 2008100985	A3	20081030		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2008216327	A1	20080821	AU 2008-216327	20080213
CA 2677651	A1	20080821	CA 2008-2677651	20080213
AR 65335	A1	20090603	AR 2008-100618	20080213
KR 2009110913	A	20091023	KR 2009-716980	20080213
EP 2120900	A2	20091125	EP 2008-729719	20080213
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR			
JP 2010519209	T	20100603	JP 2009-549693	20080213
ZA 2009005159	A	20100526	ZA 2009-5159	20090723
MX 2009008584	A	20090818	MX 2009-8584	20090811
US 20100069458	A1	20100318	US 2009-526962	20090813
CN 101626758	A	20100113	CN 2008-80005098	20090814
IN 2009DN05679	A	20100528	IN 2009-DN5679	20090902
PRAI US 2007-890005P	P	20070215		
WO 2008-US53798	W	20080213		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compns. comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a com. package comprising said combination. Thus, combination of LBH589 and velcade exhibited synergistic efficiency in treating pancreatic tumor, tested with MIA PaCa-2 cells.


IT 761437-28-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combinations of therapeutic agents comprising
 N-hydroxy-3-[4-[[[2-(2-Me-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-
 2-propenamide for treating cancer)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L9 ANSWER 29 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:916378 CAPLUS
 DN 149:224273
 TI Anthranilamide inhibitors of aurora kinase and their preparation,
 pharmaceutical compositions and use in the treatment of cancer
 IN Axten, Jeffrey Michael; Bryan, Deborah L.; Drewry, David Harold; Faltg,
 Thomas H.; Gallagher, Timothy Francis; Johnson, Neil W.; Kasperec, Jiri;
 Ralph, Jeffrey M.; Silva, Domingos J.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 98pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008092049	A1	20080731	WO 2008-US51985	20080125
	W:	AE, AG, AL, AM, AN, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AR 65015	A1	20090513	AR 2008-100292	20080124
	AU 2008027809	A1	20080731	AU 2008-207809	20080125
	CA 2676257	A1	20080731	CA 2008-2676257	20080125
	US 20080182852	A1	20080731	US 2008-19730	20080125
	US 7625903	B2	20091201		
	EP 2121637	A1	20091125	EP 2008-728247	20080125
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR			
	JP 2010516780	T	20100520	JP 2009-547435	20080125
	US 20100016318	A1	20100121	US 2009-524009	20090722
PRAI	US 2007-886676P	P	20070126		
	WO 2008-US51985	W	20080125		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 149:224273

AB The invention relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. Comps. of the invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer. Comps. of formula I wherein each R1 is H, (CH2)0-3-N(R5)2, O(CH2)2-3-N(R5)2, CON(R5)2, CO2H, etc.; R2 is H, halo, C1-3 alkyl, C1-3 alkoxy, CN, NO2, and CF3; each R3 is H, heterocycloalkyl, cycloalkyl, Ph, etc.; R4 is halo, C1-3 alkyl and C1-3 alkoxy; each R5 is independently C1-6 alkyl and COCH3; R5R5N taken together to form a (un)substituted 5- to 6-membered heterocyclic ring; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amination of 2-[(2,5-dichloro-4-pyrimidinyl)amino]benzamide with 3-(1-pyrrolidinylmethyl)aniline. All the invention compds. were evaluated for their aurora kinase inhibitory activity.


IT 1042434-40-1P 1042434-63-8P 1042434-64-9P

1042434-66-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of anthranilamide as aurora kinase inhibitors useful in the treatment of cancer)


RN 1042434-40-1 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(2-(4-morpholinyl)ethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 1042434-63-8 CAPLUS

CN Benzoic acid, 4-[[5-fluoro-4-[[2-[[[(1-methylethyl)amino]carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1042434-64-9 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-(hydroxymethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-66-1 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[(4-formylphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



IT	1042432-55-2P	1042432-56-3P	1042432-57-4P
	1042432-58-5P	1042432-59-6P	1042432-60-9P
	1042432-61-0P	1042432-62-1P	1042432-63-2P
	1042432-64-3P	1042432-65-4P	1042432-66-5P
	1042432-68-7P	1042432-70-1P	1042432-71-2P
	1042432-72-3P	1042432-73-4P	1042432-74-5P
	1042432-75-6P	1042432-76-7P	1042432-77-8P
	1042432-78-9P	1042432-79-0P	1042432-80-3P
	1042432-81-4P	1042432-82-5P	1042432-83-6P
	1042432-84-7P	1042432-86-9P	1042432-87-0P
	1042432-91-6P	1042432-92-7P	1042433-14-6P


1042433-15-7P	1042433-17-9P	1042433-18-0P
1042433-19-1P	1042433-20-4P	1042433-21-5P
1042433-22-6P	1042433-23-7P	1042433-54-4P
1042433-55-5P	1042433-56-6P	1042433-57-7P
1042433-59-9P	1042433-60-2P	1042433-61-3P
1042433-62-4P	1042433-63-5P	1042433-68-0P
1042433-69-1P	1042433-71-5P	1042433-72-6P
1042433-73-7P	1042433-74-8P	1042433-75-9P
1042433-76-0P	1042433-77-1P	1042433-78-2P
1042433-79-3P	1042433-80-6P	1042433-81-7P
1042433-82-8P	1042433-83-9P	1042433-85-1P
1042433-86-2P	1042433-87-3P	1042433-96-4P
1042433-97-5P	1042433-98-6P	1042433-99-7P
1042434-00-3P	1042434-01-4P	1042434-02-5P
1042434-03-6P	1042434-04-7P	1042434-05-8P
1042434-06-9P	1042434-12-7P	1042434-13-8P
1042434-16-1P	1042434-17-2P	1042434-19-4P
1042434-30-9P	1042434-36-5P	1042434-37-6P
1042434-41-2P	1042434-42-3P	1042434-46-7P
1042434-47-8P	1042434-49-0P	1042434-51-4P
1042434-53-6P	1042434-55-8P	1042434-57-0P
1042434-59-2P	1042434-60-5P	1042434-62-7P
1042434-67-2P	1042434-68-3P	1042434-69-4P
1042434-70-7P	1042434-71-8P	1042434-72-9P
1042434-73-0P	1042434-75-2P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of anthranilamide as aurora kinase inhibitors useful in the treatment of cancer)


RN 1042432-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-56-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-57-4 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-58-5 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-59-6 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-60-9 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-61-0 CAPLUS

CN Benzoic acid, 4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-62-1 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-63-2 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[4-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-64-3 CAPLUS
 CN Benamide, 2-[[5-chloro-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1042432-65-4 CAPLUS
 CN Benamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-66-5 CAPLUS
 CN Benamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-68-7 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-70-1 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-71-2 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-72-3 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-73-4 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(2-(4-morpholinyl)ethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-74-5 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-75-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-76-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-77-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-78-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-79-0 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-[4-(diethylamino)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-80-3 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-81-4 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042432-82-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042432-83-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042432-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 1042432-86-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 1042432-87-0 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 1042432-91-6 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylamino)ethyl]- (CA INDEX NAME)




RN 1042432-92-7 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1042433-14-6 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-15-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-17-9 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-18-0 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-19-1 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-20-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(2-(4-morpholinyl)ethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-21-5 CAPLUS

CN Benzamide, 2-[[2-[[3-[4-(diethylamino)-1-piperidinyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-22-6 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-23-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-54-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-55-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-56-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-57-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-59-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-60-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-61-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-62-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-63-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-(1-methylethyl)-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-68-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-69-1 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-71-5 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-72-6 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-73-7 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-(4-(1-methylethyl)-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-74-8 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-75-9 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-76-0 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-77-1 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-78-2 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-79-3 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[4-[(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-80-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-81-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-82-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-83-9 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-(3,4-dimethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-85-1 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-86-2 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-87-3 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro-N-methyl- (CA INDEX NAME)



RN 1042433-96-4 CAPLUS


CN Benamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042433-97-5 CAPLUS


CN Benamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042433-98-6 CAPLUS


CN Benzanide, 2-[[5-fluoro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042433-99-7 CAPLUS


CN Benzanide, 2-[[5-fluoro-2-[[4-(4-(1-methylethyl)-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-00-3 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-01-4 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-02-5 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-03-6 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-04-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN 1042434-05-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-06-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-12-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(2S)-2-hydroxypropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-13-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(2R)-2-hydroxypropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-16-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-17-2 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-19-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 1042434-30-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,3-dioxolan-2-ylmethyl)- (CA INDEX NAME)




RN 1042434-36-5 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-
(CA INDEX NAME)



RN 1042434-37-6 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-
(CA INDEX NAME)



RN 1042434-41-2 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-

pyrimidinyl]amino]-N-[2-(methylsulfinyl)ethyl]- (CA INDEX NAME)




RN 1042434-42-3 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)



RN 1042434-46-7 CAPLUS

CN Benzamide, 2-[[2-[[4-[[2-(ethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-47-8 CAPLUS


CN Benzamide, 2-[[2-[[4-[[2-(ethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-

5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)

CM 1

CRN 1042434-46-7

CMF C25 H31 F N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-49-0 CAPLUS

CN Benzamide, 2-[[[2-[[[4-[[[2-(diethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-48-9

CMF C27 H35 F N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-51-4 CAPLUS

CN Benzamide, 2-[[2-[[4-[[[2-(dimethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-50-3

CMF C25 H31 F N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-53-6 CAPLUS

CN Benzamide, 2-[[[2-[[[4-[[[2-aminoethyl)sulfonyl)methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-52-5

CMF C23 H27 F N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-55-8 CAPLUS

CN Benzamide, 2-[[[5-fluoro-2-[[[4-[[[2-(4-methyl-1-piperazinyl)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-54-7

CMF C28 H36 F N7 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-57-0 CAPLUS

CN Benzamide, 2-[[[5-fluoro-2-[[[4-[[[2-(4-morpholinyl)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-56-9

CMF C27 H33 F N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-59-2 CAPLUS

CN Benzamide, 2-[[[5-fluoro-2-[[[4-[[[2-(4-methylamino)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

10/568,367 (RCE)

CRN 1042434-58-1
CMF C24 H29 F N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 1042434-60-5 CAPLUS
CN Benzamide, 2-[[5-fluoro-2-[[4-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 1042434-62-7 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 1042434-67-2 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-68-3 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-(2-hydroxyethyl)amino)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-69-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-[(2-hydroxyethyl)sulfonyl]ethyl]amino)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-70-7 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-[[(2-methoxyethyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-71-8 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[(5R)-5-methyl-2-oxo-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-72-9 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-[(5S)-5-methyl-2-oxo-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-73-0 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042434-75-2 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



IT 1042435-07-3P 1042435-09-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of anthranilamide as aurora kinase inhibitors
 useful in the treatment of cancer)
 RN 1042435-07-3 CAPLUS
 CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-
 hydroxyethyl)sulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-
 methylethyl)- (CA INDEX NAME)




RN 1042435-09-5 CAPLUS
 CN Benzamide, 2-[[2-[[4-[(ethenylsulfonyl)methyl]phenyl]amino]-5-fluoro-4-
 pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 30 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:855179 CAPLUS
 DN 150:15783
 TI Dual Tyrosine Kinase Inhibitor for Focal Adhesion Kinase and Insulin-like Growth Factor-I Receptor Exhibits Anticancer Effect in Esophageal Adenocarcinoma In vitro and In vivo
 AU Watanabe, Nobuyuki; Takaoka, Munenori; Sakurama, Kazufumi; Tomono, Yasuko; Hatakeyama, Shinji; Ohmori, Osamu; Motoki, Takayuki; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Haisa, Minoru; Matsuo, Junji; Beer, David G.; Nagatsuka, Hitoshi; Tanaka, Noriaki; Naomoto, Yoshio
 CS Department of Gastroenterological Surgery, Transplant, and Surgical Oncology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama Citizens Hospital, Okayama, Japan
 SO Clinical Cancer Research (2008), 14(14), 4631-4639
 CODEN: CCRF4; ISSN: 1078-0432
 PB American Association for Cancer Research
 DT Journal
 LA English
 AB Focal adhesion kinase (FAK) regulates integrin and growth factor-mediated signaling pathways to enhance cell migration, proliferation, and survival, and its up-regulation correlates malignant grade and poor outcome in several types of cancer. In this study, we aimed to raise a potential therapeutic strategy using a FAK inhibitor for Barrett's esophageal adenocarcinoma. The expression status of FAK in clin. Barrett's esophageal adenocarcinoma tissues was determined by immunohistochem. Cultured esophageal adenocarcinoma cells were treated with TAE226, a specific FAK inhibitor with an addnl. effect of inhibiting insulin-like growth factor-I receptor (IGF-IR), to assess its anticancer effect in vitro. Western blot was carried out to explore a participating signaling pathway for TAE226-induced cell death. Furthermore, TAE226 was orally administered to s.c. xenograft animals to investigate its anticancer effect in vivo. Strong expression of FAK was found in 94.0% of Barrett's esophageal adenocarcinoma compared with 17.9% of Barrett's epithelia, suggesting that FAK might play a critical role in the progression of Barrett's esophageal adenocarcinoma. When esophageal adenocarcinoma cells were treated with TAE226, cell proliferation and migration were greatly inhibited with an apparent structural change of actin fiber and a loss of cell adhesion. The activities of FAK, IGF-IR, and AKT were suppressed by TAE226 and subsequent dephosphorylation of BAD at Ser136 occurred, resulting in caspase-mediated apoptosis. In vivo tumor volume was significantly reduced by oral administration of TAE226. These results suggest that TAE226, a dual tyrosine kinase inhibitor for FAK and IGF-IR, could become a new remedy for Barrett's esophageal adenocarcinoma.
 IT 761437-28-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor TAE226 exhibited anticancer effect in human Barrett's esophageal adenocarcinoma cell and mouse bearing tumor)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G	14	THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
RE.CNT	44	THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 31 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:821047 CAPLUS

DN 149:282622

TI FAK and IGF-1R interact to provide survival signals in human pancreatic adenocarcinoma cells

AU Liu, Weiguo; Bloom, David A.; Cance, William G.; Kurenova, Elena V.; Golubovskaya, Vita M.; Hochwald, Steven N.

CS Division of Surgical Oncology, University of Florida College of Medicine, Gainesville, FL, 32610, USA

SO Carcinogenesis (2008), 29(6), 1096-1107

CODEN: CRNGDP; ISSN: 0143-3334

PB Oxford University Press

DT Journal

LA English

AB Pancreatic cancer is a lethal disease accounting for the fourth leading cause of cancer death in USA. Focal adhesion kinase (FAK) and the insulin-like growth factor-I receptor (IGF-1R) are tyrosine kinases that activate common pathways, leading to increased proliferation and cell survival. Sparse information is available regarding their contribution to the malignant behavior of pancreatic cancer. We analyzed the relationship between FAK and IGF-1R in human pancreatic cancer cells, determined which downstream signaling pathways are altered following kinase inhibition or downregulation and studied whether dual kinase inhibition represents a potential novel treatment strategy in this deadly disease. Using immunoprecipitation and confocal microscopy, we show for the first time that FAK and IGF-1R physically interact in pancreatic cancer cells and that inhibition of tyrosine phosphorylation of either kinase disrupts their interaction. Decreasing phosphorylation of either FAK or IGF-1R alone resulted in little inhibition of cell viability or increased apoptosis. However, dual inhibition of FAK, using either a dominant-negative construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small molecule tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal-regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone. Dual kinase inhibition with FAK-CD and AEW-541 resulted in a marked increase in apoptosis when FAK was displaced from the focal adhesions. Inhibition of both tyrosine kinase activities via a novel single small molecule inhibitor (TAE 226), at low doses specific for FAK and IGF-1R, resulted in significant inhibition of cell viability, decrease in phosphorylation of ERK and Akt and increase in apoptosis accompanied by cleavage of Poly (ADP-ribose) polymerase (PARP) and activation of caspase-3 in pancreatic cancer cells. Thus, simultaneous inhibition of both tyrosine kinases represents a potential novel therapeutic approach in human pancreatic adenocarcinoma.


IT 761437-28-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(FAK and IGF-1R interact to provide survival signals in human pancreatic adenocarcinoma cells)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G	26	THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)
RE.CNT	35	THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 32 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:734100 CAPLUS
 DN 149:79629
 TI Preparation of N,N'-diarylpyrimidinediamine for use as protein kinase inhibitors
 IN Michellys, Pierre-Yves; Pei, Wei; Marsilje, Thomas H.; Lu, Wenshuo; Chen, Bei; Uno, Tetsuo; Jin, Yunho; Jiang, Tao
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 199pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008073687	A2	20080619	WO 2007-US85304	20071120
	WO 2008073687	A3	20080731		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2007333394	A1	20080619	AU 2007-333394	20071120
	CA 2671744	A1	20080619	CA 2007-2671744	20071120
	US 20080176881	A1	20080724	US 2007-943436	20071120
	KR 2009087127	A	20090814	KR 2009-714175	20071120
	EP 2091918	A2	20090826	EP 2007-864693	20071120
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
	JP 2010512329	T	20100422	JP 2009-540379	20071120
	AR 64197	A1	20090318	AR 2007-105497	20071207
	CR 10832	A	20090714	CR 2009-10832	20090528
	MX 2009006081	A	20090617	MX 2009-6081	20090608
	IN 2009DN03951	A	20091204	IN 2009-DN3951	20090616
	NO 2009002472	A	20090902	NO 2009-2472	20090630
	CN 101616895	A	20091230	CN 2007-80051064	20090807
PRAI	US 2006-869299P	P	20061208		
	US 2007-966449P	P	20070828		
	WO 2007-US85304	W	20071120		

OS CASREACT 149:79629; MARPAT 149:79629

AB Title compds. I [R1 and R2 independently = halo, OR12, (un)substituted alkyl, alkenyl, etc.; or one of R1 or R2 = H; or R1 and R2 together form (un)substituted monocyclic or fused carbocyclic ring, aryl, heteroaryl, etc.; R3 = CN, SO2R12, (CR5)2CO2R12, etc.; R4 = H, NO2, halo, (un)substituted alkyl, alkenyl, etc.; R5 = H or alkyl; R6 = substituted aryl or heteroaryl; R12 = H, alkyl, aryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by amidation of 4-aminopiperidine-1-carboxylic acid tert-Bu ester with


2-chloro-4-isopropoxy-5-nitrobenzoyl chloride (preparation given), followed by coupling with vinylboronic acid di-Bu ester, cyclization, reduction, substitution with (2,5-dichloropyrimidin-4-yl)-[2-(propane-2-sulfonyl)phenyl]amine (preparation given), and deprotection. I were evaluated in BaF3-NPM-ALK cell assays and, in general, demonstrated IC50 values from 1 nM to 10 μ M.

IT 1032900-25-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N,N'-diarylpyrimidinediamine for use as protein kinase inhibitors)

RN 1032900-25-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]- (CA INDEX NAME)



IT	1032900-21-2P	1032900-23-4P	1032900-26-7P
	1032900-27-8P	1032900-34-7P	1032900-38-1P
	1032900-39-2P	1032900-51-8P	1032900-52-9P
	1032900-54-1P	1032900-55-2P	1032900-56-3P
	1032900-57-4P	1032900-58-5P	1032900-59-6P
	1032900-60-9P	1032900-62-1P	1032900-63-2P
	1032900-64-3P	1032900-65-4P	1032900-66-5P
	1032900-68-7P	1032900-69-8P	1032900-70-1P
	1032900-71-2P	1032900-79-0P	1032900-80-3P
	1032900-81-4P	1032900-83-6P	1032900-84-7P
	1032900-94-9P	1032900-95-0P	1032900-96-1P
	1032900-97-2P	1032900-98-3P	1032900-99-4P
	1032901-00-0P	1032901-02-2P	1032901-03-3P
	1032901-04-4P	1032901-05-5P	1032901-06-6P
	1032901-07-7P	1032901-09-9P	1032901-14-6P
	1032901-20-4P	1032901-23-7P	1032901-24-8P
	1032901-26-0P	1032901-30-6P	1032901-48-6P
	1032901-49-7P	1032901-50-0P	1032901-51-1P
	1032901-52-2P	1032901-65-7P	1032901-66-8P
	1032901-67-9P	1032901-68-0P	1032901-69-1P
	1032901-70-4P	1032901-71-5P	1032901-72-6P
	1032901-73-7P	1032901-74-8P	1032901-75-9P
	1032901-77-1P	1032901-78-2P	1032901-79-3P
	1032901-81-7P	1032901-82-8P	1032903-18-6P
	1032903-19-7P	1032903-20-0P	1032903-24-4P
	1032903-25-5P	1032903-26-6P	1032903-27-7P
	1032903-28-8P	1032903-29-9P	1032903-30-2P
	1032903-33-5P	1032903-34-6P	1032903-35-7P

1032903-38-0P 1032903-40-4P 1032903-42-6P

1032903-43-7P 1032903-44-8P 1032903-45-9P


1032903-47-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of N,N'-diarylpyrimidinediamine for use as protein kinase
inhibitors)


RN 1032900-21-2 CAPLUS

CN Ethanone, 1-[5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-
pyrimidinyl]amino]-2-methyl-4-(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 1032900-23-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-
[5-methyl-2-(1-methylethoxy)-4-(4-morpholinylmethyl)phenyl]- (CA INDEX
NAME)




RN 1032900-26-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-
[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]- (CA INDEX
NAME)




RN 1032900-27-8 CAPLUS

CN 1-Piperidineethanol, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]- (CA INDEX NAME)



RN 1032900-34-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[4-(dimethylamino)cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 1032900-38-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-[(1R,2S,4R)-2,4-bis(dimethylamino)cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1032900-39-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-[(1R,2S,4S)-2,4-bis(dimethylamino)cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1032900-51-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(2S)-2-piperidinyphenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1032900-52-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-


[5-methyl-2-(1-methylethoxy)-4-(2R)-2-piperidinylphenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1032900-54-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)cyclohexyl]phenyl]- (CA INDEX NAME)




RN 1032900-55-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[4-[2-(dimethylamino)ethyl]amino]cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032900-56-3 CAPLUS

CN Benzamide, 5-[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-[4-(4-methyl-1-piperazinyl)-1-cyclohexen-1-yl]- (CA INDEX NAME)




RN 1032900-57-4 CAPLUS

CN 2-Piperazinone, 4-[4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]cyclohexyl]- (CA INDEX NAME)




RN 1032900-58-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-4-[4-(methylanino)cyclohexyl]-2-(1-methylethoxy)phenyl]- (CA INDEX NAME)



RN 1032900-59-6 CAPLUS


CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 1032900-60-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[4-(1-pyrrolidinyl)cyclohexyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1032900-62-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[4-[(2-methoxyethyl)methylamino]cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 1032900-63-2 CAPLUS


CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 1032900-64-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[cis-4-(dimethylamino)cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1032900-65-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(2-piperidinyl)phenyl]- (CA INDEX NAME)




RN 1032900-66-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[4-methyl-2-(1-methylethoxy)-5-(4-piperidinyl)phenyl]- (CA INDEX NAME)



RN 1032900-68-7 CAPLUS


CN Benzamide, 2-[[[5-chloro-2-[[[4-methyl-2-(1-methylethoxy)-5-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1032900-69-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[trans-4-(dimethylamino)cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 1032900-70-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[cis-4-(4-methyl-1-piperazinyl)cyclohexyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1032900-71-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1032900-79-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-4-[cis-4-(methylamino)cyclohexyl]-2-(1-methylethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1032900-80-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-4-[trans-4-(methylamino)cyclohexyl]-2-(1-methylethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1032900-81-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[4-methyl-2-(1-methylethoxy)-5-(3-methyl-5-isoxazolyl)phenyl]- (CA INDEX NAME)




RN 1032900-83-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[4-methyl-2-(1-methylethoxy)-5-(5-methyl-1H-pyrazol-3-yl)phenyl]- (CA INDEX NAME)




RN 1032900-84-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[4-methyl-2-(1-methylethoxy)-5-(1H-pyrazol-3-yl)phenyl]- (CA INDEX NAME)




RN 1032900-94-9 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-4-(1-methylethoxy)phenyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 1032900-95-0 CAPLUS

CN Methanone, [5-[5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-4-(1-methylethoxy)phenyl]-3-isoxazolyl](4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 1032900-96-1 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-4-(1-methylethoxy)phenyl]-N-methoxy- (CA INDEX NAME)




RN 1032900-97-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-(1H-benzimidazol-2-yl)-5-methyl-2-(1-methylethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032900-98-3 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(1-pyrrolidinylmethyl)- (CA INDEX NAME)




RN 1032900-99-4 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(4-piperidinyl)- (CA INDEX NAME)




RN 1032901-00-0 CAPLUS

CN Benamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 1032901-02-2 CAPLUS

CN Benzoic acid, 4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-03-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 1032901-04-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-4-(1'-methyl[1,4'-bipiperidin]-4-yl)-2-(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 1032901-05-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 1032901-06-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(cyclobutylloxy)-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032901-07-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[1-(2-methoxyethyl)-4-piperidinyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032901-09-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 1032901-14-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-20-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(5-methoxy-2-methyl[1,1'-biphenyl]-4-yl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032901-23-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(5-methoxy-2,4'-dimethyl[1,1'-biphenyl]-4-yl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032901-24-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(4'-fluoro-5-methoxy-2-methyl[1,1'-biphenyl]-4-yl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 1032901-26-0 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-(2',4'-difluoro-5-methoxy-2-methyl[1,1'-biphenyl]-4-yl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 1032901-30-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[cis-4-(1-pyrrolidinyl)cyclohexyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1032901-48-6 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N,2-dimethyl-4-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-49-7 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1032901-50-0 CAPLUS

CN Benzamide, 5-[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(2-methyl-5-thiazolyl)-
(CA INDEX NAME)




RN 1032901-51-1 CAPLUS

CN Benzamide, 5-[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-4-(1-methylethoxy)-N-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1032901-52-2 CAPLUS


CN Benzamide, 5-[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-cyclopropyl-N-methyl-4-(1-methylethoxy)-
(CA INDEX NAME)



RN 1032901-65-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-[trans-4-(1-pyrrolidinyl)cyclohexyl]phenyl]-
(CA INDEX NAME)

Relative stereochemistry.




RN 1032901-66-8 CAPLUS
 CN Ethanol, 2-[[trans-4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]cyclohexyl]methylamino]- (CA INDEX NAME)

Relative stereochemistry.



RN 1032901-67-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[cis-4-[(2-methoxyethyl)methylamino]cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 1032901-68-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[trans-4-[(2-methoxyethyl)methylamino]cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 1032901-69-1 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-[(4R)-4-(4-methyl-1-piperazinyl)-1-cyclohexen-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1032901-70-4 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-[(4S)-4-(4-methyl-1-piperazinyl)-1-cyclohexen-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1032901-71-5 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-[[[(1R)-2-hydroxy-1-methylethyl]amino]-1-cyclohexen-1-yl]-N-methyl-4-(1-methylethoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1032901-72-6 CAPLUS


CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-[4-[[[(1S)-2-hydroxy-1-methylethyl]amino]-1-cyclohexen-1-yl]-N-methyl-4-(1-methylethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1032901-73-7 CAPLUS


CN Benzamide, 5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(4-oxo-1-cyclohexen-1-yl)- (CA INDEX NAME)



RN 1032901-74-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 4-[[5-chloro-4-[[2-[(1-

methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-5-(1-methylethoxy)-3'-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 1032901-75-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(3-piperidiny)methyl]phenyl- (CA INDEX NAME)



RN 1032901-77-1 CAPLUS


CN Ethanol, 2-[[2-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]propyl]methylamino]- (CA INDEX NAME)



RN 1032901-78-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[trans-4-(dimethylamino)cyclohexyl]-2-methoxy-5-methylphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 1032901-79-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[cis-4-(dimethylamino)cyclohexyl]-2-methoxy-5-methylphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 1032901-81-7 CAPLUS

CN Benzamide, 2-chloro-5-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-[2-(dimethylamino)ethyl]-4-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-82-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-chloro-2-(1-methylethoxy)-5-(3-methyl-5-isoxazolyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-18-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-(1-methyl-2-piperidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-19-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[1-methyl-2-(4-methyl-1-piperazinyl)ethyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-20-0 CAPLUS


CN Benzenepropanol, 4-[[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-gamma-methyl-3-(1-methylethoxy)- (CA INDEX NAME)




RN 1032903-24-4 CAPLUS
 CN Benzeneethanol, 4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-β,β-dimethyl-3-(1-methylethoxy)- (CA INDEX NAME)



RN 1032903-25-5 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)ethyl]-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-26-6 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[1-methyl-2-(1-pyrrolidinyl)ethyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-27-7 CAPLUS

CN Benzeneacetic acid, 4-[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]- α , α -dimethyl-3-(1-methylethoxy)-, methyl ester (CA INDEX NAME)




RN 1032903-28-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[1-methyl-2-(4-morpholinyl)ethyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-29-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-fluoro-2-[(1-methylethyl)sulfonyl]phenyl]-N2-[2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]- (CA INDEX NAME)




RN 1032903-30-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-fluoro-2-[(1-methylethyl)sulfonyl]phenyl]-N2-[2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]- (CA INDEX NAME)




RN 1032903-33-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-34-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-(1'-methyl[1,4'-bipiperidin]-4-yl)-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-35-7 CAPLUS

CN Cyclohexanone, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 1032903-38-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-40-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032903-42-6 CAPLUS
 CN 1-Piperidineacetamide, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]- (CA INDEX NAME)



RN 1032903-43-7 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-(1-methylethoxy)-2-(4-piperidinyl)-5-pyrimidinyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-44-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-6-(4-piperidinyl)-3-pyridinyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 1032903-45-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-6-[4-(1-piperazinyl)phenyl]-3-pyridinyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 1032903-47-1 CAPLUS

CN 1,3-Propanediol, 2-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]-2-methyl- (CA INDEX NAME)




IT 1032903-60-8P 1032903-64-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N,N'-diarylpyrimidinediamine for use as protein kinase inhibitors)

RN 1032903-60-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)-2-(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 1032903-64-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-

10/568,367 (RCE)

methylethoxy)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L9 ANSWER 33 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:605237 CAPLUS
 DN 149:44292
 TI Development and Experimental Validation of a Docking Strategy for the
 Generation of Kinase-Targeted Libraries
 AU Gozalbes, Rafael; Simon, Laurence; Froloff, Nicolas; Sartori, Eric;
 Monteils, Claude; Baudelle, Romuald
 CS Cerep, Courtaboeuf, 91951, Fr
 SO Journal of Medicinal Chemistry (2008), 51(11), 3124-3132
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 149:44292
 AB A high-throughput docking strategy for the filtering of in silico compds.
 and the generation of kinase-targeted libraries is described. Systematic
 docking and scoring in three kinase crystal 3D structures of 123
 structurally diverse kinase ligands led to the determination of six thresholds


for

each kinase. These thresholds were used as filters for the virtual
 screening of two collections of compds.: a collection of more than 2500
 drugs and drug-like compds. (neg. control) and a kinase-targeted library
 of 1440 compds. This strategy was then exptl. validated by testing 60
 compds. from the kinase-targeted library on 41 kinases from five different
 families. The 60 compds. were split into those passing all the thresholds
 and the others (30 compds. in each group). The overall hit enrichment was
 6.70-fold higher in the first group, validating our approach for the
 generation of kinase-targeted libraries and the identification of
 scaffolds with high kinase inhibitory potential.

IT 1032182-71-0 1032183-86-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (development and validation of docking strategy for generation of
 kinase-targeted libraries)
 RN 1032182-71-0 CAPLUS
 CN Benzamide, N-[2-[4-(dimethylamino)phenyl]ethyl]-4-[[2-[(3-
 methylphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1032183-86-0 CAPLUS
 CN Benzamide, N-methyl-3-[[2-[(3-methylphenyl)amino]-4-pyrimidinyl]amino]-N-
 [2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



OSC.G	9	THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT	48	THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 34 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:530636 CAPLUS

DN 149:118868

TI Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

AU McDermott, Ultan; Iafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey

CS Center for Molecular Therapeutics, Massachusetts General Hospital Cancer

Center and Harvard Medical School, Charlestown, MA, 02129, USA

SO Cancer Research (2008), 68(9), 3389-3395

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

AB Selective kinase inhibitors have had a substantial impact on the field of medical oncol. Whereas these agents can elicit dramatic clin. responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion. We have established an automated platform for examining the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify addnl. genotype-correlated responses that may be clin. relevant. Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells. This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas. ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas. Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification. Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response. These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clin. responsive to pharmacol. ALK inhibition. [Cancer Res 2008;68(9):3389-95].


IT 761439-42-3, NVP-TAE 684

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors)

RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-(CA INDEX NAME)



OSC.G	37	THERE ARE 37 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)
RE.CNT	18	THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 35 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:529900 CAPLUS
 DN 148:538288
 TI Preparation of fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors
 IN Ahmed, Gulzar; Bohnstedt, Adolph; Breslin, Henry Joseph; Burke, Jason; Curry, Matthew A.; Diebold, James L.; Dorsey, Bruce; Dugan, Benjamin J.; Feng, Daming; Gingrich, Diane E.; Guo, Tao; Ho, Koc-Kan; Learn, Keith S.; Lisko, Joseph G.; Liu, Rong-Qiang; Mesaros, Eugen F.; Mikiewicz, Karen; Ott, Gregory R.; Parrish, Jonathan; Theroff, Jay P.; Thieu, Tho V.; Tripathy, Rabindranath; Underiner, Theodore L.; Wagner, Jason C.; Weinberg, Linda; Wells, Gregory J.; You, Ming; Zificsak, Craig A.
 PA Cephalon, Inc., USA; Pharmacopeia Drug Discovery, Inc.
 SO PCT Int. Appl., 1297 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008051547	A1	20080502	WO 2007-US22496	20071023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2007309427	A1	20080502	AU 2007-309427	20071023
	CA 2669111	A1	20080502	CA 2007-2669111	20071023
	AR 63527	A1	20090128	AR 2007-104687	20071023
	JP 2010507665	T	20100311	JP 2009-534629	20071023
	EP 2222647	A1	20100901	EP 2007-861484	20071023
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
	US 20090221555	A1	20090903	US 2009-162851	20090113
	MX 2009004426	A	20090812	MX 2009-4426	20090423
	CN 101535276	A	20090916	CN 2007-80039464	20090423
PRAI	US 2006-853562P	P	20061023		
	WO 2007-US22496	W	20071023		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 148:538288


AB Title compds. I and II [R1 = H, halo, NO2, OH and derivs., aryl, alkyl, etc.; R2 = (un)substituted alk(en/yn)yl, (hetero)aryl, R3-R5 = independently H, CO2H and derivs., NH2 and derivs., OCHF2, etc.; A1-A5 = independently (CH2)1-2 and derivs., CO, NH and derivs., S, SO, SO2, O, with provisoes; with the exception of specified compds.; and their pharmaceutically acceptable salts] were prepared as ALK and c-Met kinase inhibitors for treating proliferative disorders. Thus, nitration of 1,3,4,5-tetrahydrobenzo[b]azepin-2-one with HNO3/H2SO4, alkylation with Me iodide, reduction of the nitro intermediate and amination of 2-[(2,5-dichloropyrimidin-4-yl)amino]-N-methylbenzamide gave

benzazepinylaminopyrimidine III. III inhibited ALK and C-Met kinases with $IC_{50} < 0.1 \mu M$.

IT 1022965-78-1P, 2-[2-[[3-(3-Amino-3-oxopropyl)-4-(prop-1-en-2-yl)phenyl]amino]-5-chloropyrimidin-4-ylamino]-3-fluoro-N-methylbenzamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)

RN 1022965-78-1 CAPLUS

CN Benzenepropanamide, 5-[[5-chloro-4-[[2-fluoro-6-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-(1-methylethenyl)- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 36 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:474245 CAPLUS
 DN 148:447347
 TI An oncogene arising from a fusion of the EML4 and ALK genes of human and
 its use in the diagnosis and treatment of cancers
 IN Mano, Hiroyuki; Kuromitsu, Sadao; Shindo, Nobuaki; Soga, Takatoshi;
 Furutani, Takashi
 PA Astellas Pharma Inc., Japan; Curegene K.K.
 SO Can. Pat. Appl., 156pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2598893	A1	20080411	CA 2007-2598893	20070824
	US 20080090776	A1	20080417	US 2007-845498	20070827
	US 7728120	B2	20100601		
	EP 1914240	A1	20080423	EP 2007-254044	20071011
	EP 1914240	B1	20091202		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2008295444	A	20081211	JP 2007-265917	20071011
	JP 4303303	B2	20090729		
	EP 2116553	A1	20091111	EP 2009-6058	20071011
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
	AT 450547	T	20091215	AT 2007-254044	20071011
	ES 2335368	T3	20100325	ES 2007-254044	20071011
	US 20090099193	A1	20090416	US 2008-100595	20080410
	US 7605131	B2	20091020		
	JP 2009100783	A	20090514	JP 2009-35918	20090218
PRAI	JP 2006-277718	A	20061011		
	JP 2007-120670	A	20070501		
	CA 2007-2598893	A	20070824		
	EP 2007-254044	A3	20071011		
	JP 2007-265917	A	20071011		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A chimeric gene arising from a fusion of the EML4 and ALK genes as a
 result of an inversion on human chromosome 2 is identified in a number of
 cancers. Detection of the oncogene, or its gene product, may be useful in
 the diagnosis of cancers, and the gene product may be a target for drug
 therapy. The fusion gene mRNA was identified in a lung adenocarcinoma
 patient and was found in tissue from non-small cell lung cancer patients.
 The fusion protein is active as a kinase, retaining the kinase activity of
 the ALK anaplastic lymphoma kinase gene product. Inhibitors of the kinase
 activity were effective at inhibiting growth of cells expressing the
 oncogene. siRNAs directed against the mRNA of the chimeric gene were also
 effective at inhibiting cell proliferation.


IT 761439-42-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as kinase inhibitor of EML4-ALK fusion protein; oncogene arising from
 fusion of EML4 and ALK genes of human and its use in diagnosis and
 treatment of cancers)


RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-

piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)



L9 ANSWER 37 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:161408 CAPLUS
 DN 149:143328
 TI TAE226 Inhibits Human Neuroblastoma Cell Survival
 AU Beierle, Elizabeth A.; Trujillo, Angelica; Nagaram, Abhilasha;
 Golubovskaya, Vita M.; Cance, William G.; Kurenova, Elena V.
 CS Department of Surgery, College of Medicine, University of Florida,
 Gainesville, FL, USA
 SO Cancer Investigation (2008), 26(2), 145-151
 CODEN: CINVD7; ISSN: 0735-7907
 PB Informa Healthcare
 DT Journal
 LA English
 AB Purpose. Neuroblastoma is one of the most devastating pediatric solid tumors and is unresponsive to many interventions. TAE226 is a novel small mol. FAK inhibitor. We investigated the effects of TAE226 on neuroblastoma cells in vitro. Materials and Methods. Human neuroblastoma cell lines were treated with varying concns. of TAE226. Following treatment, cell viability, cell cycle, and apoptosis were evaluated. Results. Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis. Conclusions. Targeting FAK provides potential therapeutic options for the treatment of neuroblastoma and deserves further investigation.
 IT 761437-28-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TAE226 decreased focal adhesion kinase Y397 phosphorylation, viability, resulted cell cycle arrest and increased apoptosis in human neuroblastoma cell)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 38 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:21101 CAPLUS

DN 148:276277

TI Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

AU McDermott, Ultan; Sharma, Sreenath V.; Dowell, Lori; Greninger, Patricia; Montagut, Clara; Lamb, Jennifer; Archibald, Heidi; Raudales, Raul; Tam, Angela; Lee, Diana; Rothenberg, S. Michael; Supko, Jeffrey G.; Sordella, Raffaella; Ulkus, Lindsey E.; Lafrate, A. John; Maheswaran, Shyamala; Njauw, Ching Ni; Tsao, Hensin; Drew, Lisa; Hanke, Jeff H.; Ma, Xiao-Jun; Erlander, Mark G.; Gray, Nathanael S.; Haber, Daniel A.; Settleman, Jeffrey

CS Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA

SO Proceedings of the National Academy of Sciences of the United States of America (2007), 104(50), 19936-19941
CODEN:PNASAG; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

AB Kinase inhibitors constitute an important new class of cancer drugs, whose selective efficacy is largely determined by underlying tumor cell genetics. The authors established a high-throughput platform to profile 500 cell lines derived from diverse epithelial cancers for sensitivity to 14 kinase inhibitors. Most inhibitors were ineffective against unselected cell lines but exhibited dramatic cell killing of small non-overlapping subsets. Cells with exquisite sensitivity to EGFR, HER2, MET, or BRAF kinase inhibitors were marked by activating mutations or amplification of the drug target. Although most cell lines recapitulated known tumor-associated genotypes, the screen revealed low-frequency drug-sensitizing genotypes in tumor types not previously associated with drug susceptibility. Furthermore, comparing drugs thought to target the same kinase revealed striking differences, predictive of clin. efficacy. Genetically defined cancer subsets, irresp. of tissue type, predict response to kinase inhibitors, and provide an important preclin. model to guide early clin. applications of novel targeted inhibitors.


IT 761439-42-3, NVP-TAE684

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling)


RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




OSC.G	55	THERE ARE 55 CAPLUS RECORDS THAT CITE THIS RECORD (55 CITINGS)
RE.CNT	21	THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 39 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:1306239 CAPLUS
 DN 148:623
 TI Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma
 AU Halder, Jyotsnabaran; Lin, Yvonne G.; Merritt, William M.; Spannuth, Whitney A.; Nick, Alpa M.; Honda, Toshiyuki; Kamat, Aparna A.; Han, Liz Y.; Kim, Tae Jin; Lu, Chunhua; Tari, Ana M.; Bornmann, William; Fernandez, Ariel; Lopez-Berestein, Gabriel; Sood, Anil K.
 CS Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
 SO Cancer Research (2007), 67(22), 10976-10983
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 AB Focal adhesion kinase (FAK) overexpression is frequently found in ovarian and other cancers and is predictive of poor clin. outcome. In the current study, we characterized the biol. and therapeutic effects of a novel FAK inhibitor, TAE226. Taxane-sensitive (SKOV3i.p.1 and HeyA8) and taxane-resistant (HeyA8-MDR) cell lines were used for in vitro and in vivo therapy expts. using TAE226 alone and in combination with docetaxel. Assessment of cytotoxicity, cell proliferation [proliferating cell nuclear antigen (PCNA)], angiogenesis (CD31), and apoptosis (terminal nucleotidyl transferase-mediated nick end labeling) were done by immunohistochem. and immunofluorescence. In vitro, TAE226 inhibited the phosphorylation of FAK at both Y397 and Y861 sites, inhibited cell growth in a time- and dose-dependent manner, and enhanced docetaxel-mediated growth inhibition by 10- and 20-fold in the taxane-sensitive and taxane-resistant cell lines, resp. In vivo, FAK inhibition by TAE226 significantly reduced tumor burden in the HeyA8, SKOV3i.p.1, and HeyA8-MDR models (46-64%) compared with vehicle-treated controls. However, the greatest efficacy was observed with concomitant administration of TAE226 and docetaxel in all three models (85-97% reduction, all P values <0.01). In addition, TAE226 alone and in combination with chemotherapy significantly prolonged survival in tumor-bearing mice. Even in larger tumors, combination therapy with TAE226 and docetaxel resulted in tumor regression. The therapeutic efficacy was related to reduced pericyte coverage, induction of apoptosis of tumor-associated endothelial cells, and reduced microvessel d. and tumor cell proliferation. The novel FAK inhibitor, TAE226, offers an attractive therapeutic approach in ovarian carcinoma.
 IT 761437-28-9
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antitumor efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G	33	THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)
RE.CNT	49	THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 40 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:746527 CAPLUS
 DN 147:202997
 TI N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics
 AU Bamborough, Paul; Angell, Richard M.; Bhamra, Inder; Brown, David; Bull, James; Christopher, John A.; Cooper, Anthony W. J.; Fazal, Lynsey H.; Giordano, Ilaria; Hind, Lucy; Patel, Vipulkumar K.; Ranshaw, Lisa E.; Sims, Martin J.; Skone, Philip A.; Smith, Kathryn J.; Vickerstaff, Emma; Washington, Melanie
 CS Medicines Research Centre, GlaxoSmithKline R&D, Hertfordshire, SG1 2NY, UK
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4363-4368
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 147:202997
 AB 2,4-Dianilino pyrimidines are well-known inhibitors of tyrosine kinases including lymphocyte specific kinase (Lck). Structure-activity relationships at the 4-position are discussed and rationalized. Examples bearing a 2-methyl-5-hydroxyaniline substituent at the 4-position were especially potent but showed poor oral pharmacokinetics. Replacement of this substituent by 4-amino-5-methyl-1H-indazole yielded compds. with comparable enzyme potency and improved pharmacokinetic properties.
 IT 944795-19-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pyrimidinylindazolamine inhibitors of Lck as phenol isosteres with improved pharmacokinetics)
 RN 944795-19-1 CAPLUS
 CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N,4-trimethyl- (CA INDEX NAME)



OSC.G 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 41 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2007:667606 CAPLUS

DN 147:63669

TI A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

AU Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.

CS Department of Surgery, Duke University Medical Center, Durham, NC, USA

SO Molecular Carcinogenesis (2007), 46(6), 488-496

CODEN: MOCAE8; ISSN: 0899-1987

PB Wiley-Liss, Inc.

DT Journal

LA English

AB Glioblastomas are highly lethal cancers that resist current therapies. Novel therapies under development target mol. mechanisms that promote glioblastoma growth. In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed. Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on critical tyrosine residues. Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation. We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925. As all glioma cell lines examined expressed phosphorylated FAK, we examined the efficacy of a novel low-mol. weight inhibitor of FAK, TAE226, against human glioma cell lines. TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines. TAE226 induced a concentration-dependent decrease


in cellular proliferation with an associated G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner. TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.

IT 761437-28-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low-mol. weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth)


RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




OSC.G	38	THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (38 CITINGS)
RE.CNT	19	THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 42 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:412514 CAPLUS
 DN 147:28253
 TI Inhibition of both focal adhesion kinase and insulin-like growth factor-I
 AU Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu;
 Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung,
 W. K. Alfred
 CS Brain Tumor Center, Department of Neuro-Oncology, The University of Texas
 M. D. Anderson Cancer Center, USA
 SO Molecular Cancer Therapeutics (2007) 6(4), 1357-1367
 CODEN: MCTOCF; ISSN: 1535-7163
 PB American Association for Cancer Research
 DT Journal
 LA English
 AB Multiple genetic aberrations in human gliomas contribute to their highly
 infiltrative and rapid growth characteristics. Focal adhesion kinase
 (FAK) regulates tumor migration and invasion. Insulin-like growth
 factor-I receptor (IGF-IR), whose expression correlates with tumor grade,
 is involved in proliferation and survival. We hypothesized that
 inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter
 called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR,
 would suppress the growth and invasion of glioma cells. In culture,
 TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK
 (Tyr397). TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR
 and activity of its downstream target genes such as MAPK and Akt. TAE226
 retarded tumor cell growth as assessed by a cell viability assay and
 attenuated G2-M cell cycle progression associated with a decrease in cyclin
 B1 and phosphorylated cdc2 (Tyr15) protein expression. TAE226 treatment
 inhibited tumor cell invasion by at least 50% compared with the control in
 an in vitro Matrigel invasion assay. Interestingly, TAE226 treatment of
 tumor cells containing wild-type p53 mainly exhibited G2-M arrest, whereas
 tumor cells bearing mutant p53 underwent apoptosis. Induction of
 apoptosis by TAE226 was substantiated by detection of caspase-3/7
 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V
 apoptosis assay. More importantly, TAE226 treatment significantly
 increased the survival rate of animals in an intracranial glioma xenograft
 model. Collectively, these data show that blocking the signaling pathways
 of FAK and IGF-IR with TAE226 has the potential to be an efficacious
 treatment for human gliomas.
 IT 761437-28-9, NVP-TAE 226
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibition of FAK and IGF-I receptor kinase-related mutated
 p53-regulated multiple pathways suppressed glioma proliferation by
 TAE226)
 RN 761437-28-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




OSC.G	42	THERE ARE 42 CAPLUS RECORDS THAT CITE THIS RECORD (42 CITINGS)
RE.CNT	45	THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 43 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:203037 CAPLUS
 DN 146:434402
 TI Identification of NVP-TAE684, a potent, selective, and efficacious
 inhibitor of NPM-ALK. [Erratum to document cited in CA146:308635]
 AU Galkin, Anna V.; Melnick, Jonathan S.; Kim, Sungjoon; Hood, Tami L.; Li,
 Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Jiang,
 Jiqing; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter
 G.; Gray, Nathanael S.; Warmuth, Markus
 CS Kinase Lead Discovery, Departments of Pharmacology and Medicinal
 Chemistry, Genomics Institute of the Novartis Research Foundation, San
 Diego, CA, 92121, USA
 SO Proceedings of the National Academy of Sciences of the United States of
 America (2007), 104(6), 2025
 CODEN: PNASAG; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 AB The first two authors, Anna V. Galkin and Jonathan S. Melnick, contributed
 equally to the work.
 IT 761439-42-3, NVP-TAE 684
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NVP-TAE684 as selective inhibitor of NPM-ALK protein in anaplastic
 large cell lymphomas (Erratum))
 RN 761439-42-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-
 piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
 (CA INDEX NAME)



L9 ANSWER 44 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:32903 CAPLUS
 DN 146:308635
 TI Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
 AU Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus
 CS Kinase Lead Discovery, Departments of Pharmacology and Medicinal Chemistry, Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA
 SO Proceedings of the National Academy of Sciences of the United States of America (2007), 104(1), 270-275
 CODEN:PNAS66, ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 AB Constitutive overexpression and activation of NPM-ALK fusion protein [t(2;5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs). We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM. NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest. In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas. NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.
 IT 761439-42-3, NVP-TAE 684
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NVP-TAE684 as selective inhibitor of NPM-ALK protein in anaplastic large cell lymphomas)
 RN 761439-42-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-(CA INDEX NAME)



OSC.G 42 THERE ARE 42 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/568,367 (RCE)

L9 ANSWER 45 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:1256680 CAPLUS
 DN 146:20278
 TI 2,4-Pyrimidinediamine compound JAK kinase inhibitors, and their
 therapeutic use
 IN Wong, Brian
 PA Rigel Pharmaceuticals, Inc., USA
 SO U.S. Pat. Appl. Publ., 26pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060270694	A1	20061130	US 2006-416652	20060502
	CA 2604551	A1	20070308	CA 2006-2604551	20060502
	WO 2007027238	A2	20070308	WO 2006-US17008	20060502
	WO 2007027238	A3	20070913		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1883302	A2	20080206	EP 2006-824733	20060502
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2008540436	T	20081120	JP 2008-510173	20060502
PRAI	US 2005-678241P	P	20050503		
	WO 2006-US17008	W	20060502		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention provides 2,4-pyrimidinediamine compds. that selectively
 inhibit JAK kinase as compared to Syk kinase, as well as various methods
 of using the JAK-selective compds. for treating e.g. an immune-related
 disease.
 IT 916044-26-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pyrimidinediamine compound JAK kinase inhibitors, and therapeutic use)
 RN 916044-26-3 CAPLUS
 CN Glycine, N-[4-[5-fluoro-2-[(3-hydroxyphenyl)amino]-4-
 pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L9 ANSWER 46 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:513675 CAPLUS
 DN 145:34151
 TI Combinations of JAK kinase inhibitors
 IN Cooke, Nigel Graham; Manley, Paul W.
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006056399	A2	20060601	WO 2005-EP12480	20051122
	WO 2006056399	A3	20060831		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005309019	A1	20060601	AU 2005-309019	20051122
	CA 2586605	A1	20060601	CA 2005-2586605	20051122
	CN 101106983	A	20080116	CN 2005-80046883	20051122
	EP 1885352	A2	20080213	EP 2005-814596	20051122
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2008520612	T	20080619	JP 2007-541823	20051122
	BR 2005017887	A	20081021	BR 2005-17887	20051122
	IN 2007DN03463	A	20070831	IN 2007-DN3463	20070509
	US 20090156602	A1	20090618	US 2007-719838	20070521
	MX 2007006204	A	20070620	MX 2007-6204	20070523
	KR 2007085433	A	20070827	KR 2007-711743	20070523
PRAI	US 2004-630713P	P	20041124		
	WO 2005-EP12480	W	20051122		
AB	The invention provides a pharmaceutical combination comprising (a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and (b) at least one JAK kinase inhibitor, and a method for treating or preventing a proliferative disease using such a combination. A preferred embodiment of the invention is the combination of a RAF inhibitor, e.g., (4-tert-butylphenyl)-(4-pyridin-4-yl-methyl-isoquinolin-1-yl)amine or [4,7']bi-isoquinolinyl-1-yl-4-(tert-butylphenyl)amine, and a JAK kinase inhibitor, such as PNU 156804 or WHI-P 131 for the treatment of myelomas, especially multiple myeloma.				
IT	761437-28-9				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combinations of JAK kinase inhibitors with other protein kinase inhibitors for treatment or prevention of proliferative disease)				
RN	761437-28-9	CAPLUS			
CN	Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)				



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 47 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2006:193590 CAPLUS

DN 144:274291

TI Preparation of bis(arylamino)pyrimidine derivatives as antitumor agents

IN Imbach, Patricia; Kawahara, Eiji; Konishi, Kazuhide; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Roesel, Johannes; Teno, Naoki; Umemura, Ichiro

PA Novartis AG, Switz.; Novartis Pharma GmbH

SO PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021454	A2	20060302	WO 2005-EP9251	20050826
	WO 2006021454	A3	20060504		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005276582	A1	20060302	AU 2005-276582	20050826
	AU 2005276582	B2	20090716		
	CA 2577251	A1	20060302	CA 2005-2577251	20050826
	EP 1784392	A2	20070516	EP 2005-776772	20050826
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	AR 54081	A1	20070606	AR 2005-103592	20050826
	CN 101048386	A	20071003	CN 2005-80036888	20050826
	JP 2008510763	T	20080410	JP 2007-528754	20050826
	BR 2005014681	A	20080617	BR 2005-14681	20050826
	ZA 2007001406	A	20080827	ZA 2007-1406	20070215
	IN 2007DN01410	A	20070824	IN 2007-DN1410	20070221
	MX 2007002254	A	20070420	MX 2007-2254	20070223
	HR 2007000076	A2	20070731	HR 2007-76	20070226
	KR 2007054223	A	20070528	KR 2007-706800	20070326
	NO 2007001593	A	20070522	NO 2007-1593	20070327
	US 20090131436	A1	20090521	US 2009-574019	20090112
PRAI	GB 2004-19161	A	20040827		
	WO 2005-EP9251	W	20050826		

OS CASREACT 144:274291; MARPAT 144:274291

AB Title comds. I [R1 = H, (substituted) 5- or 6-membered heterocyclyl; R2 = H; R3 = (substituted) sulfamoyl, carbamoyl, 5- or 6-membered heterocyclyl; R2R3 together with N to which they are attached form heterocyclyl; R5 = halo; R7 = H, alkoxy, carbamoyl, (substituted) 5- or 6-membered heterocyclyl; R8 = H, halo, alkoxy, carbamoyl, (substituted) 5- or 6-membered heterocyclyl; R7R8 together form a 6-membered heterocyclyl; R9 = H, (substituted) 5- or 6-membered heterocyclyl; R10 = H, alkoxy], or salts thereof, were prepared For example, title compound II was prepared from

2-(2,5-dichloropyrimidin-4-ylamino)-N-isobutylbenzenesulfonamide and 4-amino-3-methoxy-N-methylbenzamide. I inhibited ALK (anaplastic lymphoma kinase) with IC50 = 0.01-1 μ M.


IT 878158-62-4P 878158-63-5P 878158-64-6P
878159-13-8P 878159-14-9P 878159-15-0P
878159-16-1P 878159-17-2P 878159-18-3P
878159-19-4P 878159-20-7P 878159-60-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bis(arylamino)pyrimidine derivs. as kinase inhibitors and antitumor agents)

RN 878158-62-4 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl- (CA INDEX NAME)



RN 878158-63-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878158-64-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-13-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-14-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 878159-15-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 878159-16-1 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 878159-17-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin-1'-yl-2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878159-18-3 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin-1'-yl-2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878159-19-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-(4-hydroxy-1-piperidinyl)-N-methyl- (CA INDEX NAME)




RN 878159-20-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-(4-hydroxy-1-piperidinyl)-N-methyl- (CA INDEX NAME)



RN 878159-60-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-(4-ethyl-1-piperazinyl)-2-methoxyphenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



OSC.G	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:158647 CAPLUS

DN 142:261547

TI Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

IN Garcia-echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya, Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro; Steensma, Ruo; Chopiuk, Greg; Jiang, Jiqing; Wan, Yongqin; Ding, Qiang; Zhang, Qiong; Gray, Nathanael Schiander; Karanewsky, Donald

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; IRM LLC

SO PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

Applicant's

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016894	A1	20050224	WO 2004-EP9099	20040813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004264382	A1	20050224	AU 2004-264382	20040813
	CA 2533320	A1	20060224	CA 2004-2533320	20040813
	EP 1660458	A1	20060531	EP 2004-764093	20040813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1832929	A	20060913	CN 2004-80022725	20040813
	BR 2004013616	A	20061017	BR 2004-13616	20040813
	JP 2007502260	T	20070208	JP 2006-522998	20040813
	SG 145749	A1	20080929	SG 2008-6063	20040813
	RU 2395500	C2	20100727	RU 2006-107785	20040813
	KR 2006039938	A	20060509	KR 2006-7003056	20060214
	KR 904570	B1	20090625		
	MX 2006001759	A	20060512	MX 2006-1759	20060214
	IN 2006CN00553	A	20070706	IN 2006-CN553	20060214
	IN 240560	A1	20100528		
	NO 2006001214	A	20060515	NO 2006-1214	20060315
	US 20080132504	A1	20080605	US 2006-568367	20060818
	AU 2008229685	A1	20081030	AU 2008-229685	20080929
FRAI	GB 2003-19227	A	20030815		
	GB 2003-22370	A	20030924		
	AU 2004-264382	A3	20040813		
	WO 2004-EP9099	W	20040813		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:261547; MARPAT 142:261547

AB The title compds. I [R = aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R0-R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, etc.], useful for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition

of FAK and/or ALK and/or ZAP-70 and/or IGF-IR, were prepared and formulated. E.g., a 2-step synthesis of II, starting from 2,4-dichloro-5-nitropyrimidine and 2-amino-N-methylbenzenesulfonamide, was given. The compds. I have IC₅₀ values in the range of 10 nM to 2 μ M in cell-free ZAP-70 kinase assay.

IT	761437-28-9P	761437-29-0P	761437-30-3P
	761437-31-4P	761437-32-5P	761437-33-6P
	761437-34-7P	761437-35-8P	761437-36-9P
	761437-37-0P	761437-39-2P	761437-40-5P
	761437-41-6P	761437-42-7P	761437-43-8P
	761437-44-9P	761437-45-0P	761437-46-1P
	761437-47-2P	761437-48-3P	761437-49-4P
	761437-50-7P	761437-51-8P	761437-52-9P
	761437-53-0P	761437-54-1P	761437-55-2P
	761437-59-6P	761437-60-9P	761437-61-0P
	761437-62-1P	761437-63-2P	761437-64-3P
	761437-65-4P	761437-66-5P	761437-67-6P
	761437-68-7P	761437-69-8P	761437-70-1P
	761437-71-2P	761437-72-3P	761437-73-4P
	761437-74-5P	761437-76-7P	761437-84-7P
	761437-85-8P	761437-86-9P	761437-88-1P
	761437-91-6P	761437-92-7P	761437-93-8P
	761437-94-9P	761437-95-0P	761437-96-1P
	761437-97-2P	761438-00-0P	761438-89-5P
	761438-90-8P	761438-91-9P	761438-92-0P
	761438-93-1P	761438-95-3P	761438-96-4P
	761438-97-5P	761438-98-6P	761439-00-3P
	761439-01-4P	761439-02-5P	761439-03-6P
	761439-04-7P	761439-05-8P	761439-06-9P
	761439-07-0P	761439-08-1P	761439-09-2P
	761439-10-5P	761439-11-6P	761439-12-7P
	761439-13-8P	761439-14-9P	761439-15-0P
	761439-16-1P	761439-17-2P	761439-18-3P
	761439-19-4P	761439-20-7P	761439-21-8P
	761439-22-9P	761439-23-0P	761439-24-1P
	761439-25-2P	761439-26-3P	761439-27-4P
	761439-28-5P	761439-29-6P	761439-30-9P
	761439-31-0P	761439-32-1P	761439-33-2P
	761439-34-3P	761439-35-4P	761439-36-5P
	761439-37-6P	761439-38-7P	761439-39-8P
	761439-40-1P	761439-41-2P	761439-42-3P
	761439-43-4P	761439-44-5P	761439-45-6P
	761439-46-7P	761439-47-8P	761439-48-9P
	761439-49-0P	761439-50-3P	761439-51-4P
	761439-52-5P	761439-53-6P	761439-54-7P
	761439-55-8P	761439-56-9P	761439-57-0P
	761439-58-1P	761439-59-2P	761439-60-5P
	761439-61-6P	761439-62-7P	761439-63-8P
	761439-64-9P	761439-65-0P	761439-66-1P
	761439-67-2P	761439-81-0P	761439-82-1P
	761439-85-4P	761439-86-5P	761439-94-5P
	761439-95-6P	845811-15-6P	845811-16-7P
	845811-17-8P	845811-35-0P	845811-36-1P
	845811-37-2P	845811-38-3P	845811-39-4P
	845811-40-7P	845811-41-8P	845811-43-0P
	845811-44-1P	845811-45-2P	845811-46-3P
	845811-47-4P	845811-54-3P	845811-55-4P


845811-62-3P	845811-63-4P	845811-69-0P
845811-70-3P	845811-71-4P	845811-72-5P
845811-73-6P	845811-74-7P	845811-75-8P
845811-76-9P	845811-77-0P	845811-78-1P
845811-80-5P	845811-81-6P	845811-83-8P
845811-84-9P	845811-86-1P	845811-88-3P
845811-89-4P	845812-23-9P	845812-41-1P
845812-49-9P	845812-51-3P	845812-56-8P
845812-61-5P	845812-66-0P	845812-70-6P
845812-73-9P	845812-77-3P	845812-81-9P
845812-85-3P	845812-86-4P	845812-90-0P
845812-96-6P	845812-97-7P	845813-01-6P
845813-05-0P	845813-08-3P	845813-19-6P
845813-20-9P	845813-24-3P	845813-25-4P
845813-29-8P	845813-40-3P	845813-66-3P
845813-67-4P	845813-71-0P	845813-75-4P
845813-76-5P	845814-12-2P	845814-14-4P
845814-16-6P	845814-22-4P	845814-25-7P
845814-26-8P	845814-43-9P	845814-44-0P
845814-45-1P	845814-46-2P	845814-51-9P
845814-52-0P	845814-53-1P	845814-54-2P
845814-80-4P	845814-82-6P	845814-83-7P
845814-84-8P	845814-90-6P	845814-91-7P
845814-99-5P	845815-01-2P	845815-04-5P
845815-05-6P	845815-07-8P	845815-08-9P
845815-10-3P	845815-11-4P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)


RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-29-0 CAPLUS


CN Benzamide, 2-[[2-[[4-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-30-3 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-
[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-
(CA INDEX NAME)

RN 761437-31-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-
piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


RN 761437-32-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(2-(4-
morpholinyl)ethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX
NAME)




RN 761437-33-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-34-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-35-8 CAPLUS

CN Benzamide, 2-[[2-[[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-36-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-hydroxy-1-piperidiny1)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-37-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(2-ethoxyethoxy)-1-piperidiny1]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-39-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(2-methoxyethoxy)-1-piperidiny1]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-40-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-42-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[4-[[5-chloro-4-[[2-(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761437-43-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-44-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-45-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-46-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-47-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 761437-48-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-49-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-

piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-50-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-51-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-52-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-53-0 CAPLUS


CN Benamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-54-1 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-59-6 CAPLUS

CN Benzamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-60-9 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-61-0 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-62-1 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-63-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-64-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-65-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-66-5 CAPLUS


CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-67-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 761437-68-7 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-69-8 CAPLUS
 CN Benzamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-

chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-70-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-71-2 CAPLUS

CN Benzamide, 2-[[2-[[4-[(1,4'-bipiperidin-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-72-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-73-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-74-5 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-bipiperidin-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-76-7 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 761437-85-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761437-86-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 761437-88-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-5-fluoro- (CA INDEX NAME)




RN 761437-91-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 761437-92-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 761437-93-8 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 761437-94-9 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)



RN 761437-95-0 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)

pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 761437-96-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-5-methoxy-N-methyl- (CA INDEX NAME)



RN 761437-97-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-00-0 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


10/568,367 (RCE)

chloro-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)




RN 761438-89-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761438-90-8 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761438-91-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761438-92-0 CAPLUS

CN 4-Piperidinol, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-93-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-95-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N-methyl- (CA INDEX NAME)




RN 761438-96-4 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-2,6-dimethyl-1-piperazinyl]- (CA INDEX NAME)




RN 761438-97-5 CAPLUS

CN 1-Propanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761438-98-6 CAPLUS

CN 1-Propanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)



RN 761439-00-3 CAPLUS


CN Ethanone, 1-[4-[[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-2,2-dimethyl-1-piperazinyl]- (CA INDEX NAME)



RN 761439-01-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761439-02-5 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761439-03-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-04-7 CAPLUS

CN Ethanone, 1-[4-[3-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-05-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[[2-(4-morpholinyl)ethyl]amino]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-06-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-(4-morpholinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-07-0 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenoxy]ethyl]- (CA INDEX NAME)



RN 761439-08-1 CAPLUS


CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxybenzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 761439-09-2 CAPLUS


CN Methanone, [4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-

pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinyl- (CA INDEX NAME)




RN 761439-10-5 CAPLUS

CN 1-Piperazineacetamide, 4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761439-11-6 CAPLUS

CN 2-Piperazinone, 4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-12-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-13-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-14-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-15-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-16-1 CAPLUS

CN 4-Piperidinemethanol, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-17-2 CAPLUS

CN 3-Pyrrolidinol, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-18-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-19-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(4-fluoro-2-methoxyphenyl)-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-20-7 CAPLUS

CN Ethanone, 1-[4-[2-[3-[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenoxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-21-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-22-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-23-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-24-1 CAPLUS

CN 4-Piperidinol, 1-[3-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenyl]- (CA INDEX NAME)




RN 761439-25-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-26-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-27-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)

methoxyphenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-28-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenyl]- (CA INDEX NAME)




RN 761439-29-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 761439-30-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl)-5-chloro-N4-[2-(ethylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-31-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]- (CA INDEX NAME)




RN 761439-32-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 761439-33-2 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-(ethylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-34-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(ethylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761439-35-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)



RN 761439-36-5 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(ethylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761439-37-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 761439-38-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-39-8 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-40-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-41-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-42-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-43-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[2-methyl-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 761439-44-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(2-methoxy-4-nitrophenyl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-45-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-46-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-47-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(methoxymethyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-48-9 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-49-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-(4-ethyl-1-piperazinyl)-2-methoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-50-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-{4-(4-morpholinyl)-1-piperidinyl}phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-51-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-{4-(1-methylethyl)-1-piperazinyl}phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-52-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-{[5-chloro-4-{[2-[(1-methylethyl)sulfonyl]phenyl]amino}-2-pyrimidinyl]amino}-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-53-6 CAPLUS

CN 4-Piperidinol, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-54-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(3-methoxy-1-pyrrolidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-55-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-methoxy-1-piperidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-56-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[(1-methyl-4-piperidinyloxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-57-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(methyamino)-1-piperidinyloxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-58-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[3-(methyamino)-1-pyrrolidinyloxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-59-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[3-(dimethylamino)-1-pyrrolidinyloxy]-2-methoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-60-5 CAPLUS

CN 2-Piperazinone, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-methyl- (CA INDEX NAME)




RN 761439-61-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-62-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-63-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[(9aS)-hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-2-yl]-2-methoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 761439-64-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761439-65-0 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761439-66-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-(4-morpholinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-67-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-(2,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 761439-81-0 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-[(2-methylpropyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-82-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]-N4-[2-[(2-methylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-85-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(butylsulfonyl)phenyl]-5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 761439-86-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-methoxy-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 761439-94-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(4-fluoro-2-methoxyphenyl)-N4-[4-(4-methyl-1-piperazinyl)-2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-95-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 845811-15-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-(4-morpholinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 845811-16-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 845811-17-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 845811-35-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845811-36-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845811-37-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845811-38-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845811-39-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845811-40-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-41-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]- (CA INDEX NAME)




RN 845811-43-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-ethoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]- (CA INDEX NAME)



RN 845811-44-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]- (CA INDEX NAME)



RN 845811-45-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[4-(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845811-46-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]- (CA INDEX NAME)



RN 845811-47-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-54-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-([1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845811-55-4 CAPLUS


CN Benzamide, 2-[[[2-[(4-{[1,4'-bipiperidin]-1'-yl}-2-ethoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl]- (CA INDEX NAME)



RN 845811-62-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-63-4 CAPLUS


CN Benzamide, 2-[5-chloro-2-[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-69-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-70-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-71-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)



RN 845811-72-5 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 845811-73-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845811-74-7 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845811-75-8 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-76-9 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-77-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845811-78-1 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin-1'-yl-2-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-80-5 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin-1'-yl-2-[[5-chloro-4-[[2-(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-86-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1,1-dimethylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-
(CA INDEX NAME)




RN 845811-88-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)




RN 845811-89-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845812-23-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845812-41-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845812-49-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845812-51-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-56-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 845812-61-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[[(1-methyl-4-piperidinyl)oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845812-66-0 CAPLUS

CN Methanone, [3-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 845812-70-6 CAPLUS

CN Methanone, [3-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-4-(1-methylethoxy)phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 845812-73-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845812-77-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl-2-(1-methylethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845812-81-9 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845812-85-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 845812-86-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845812-90-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845812-96-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(butylsulfonyl)phenyl]-5-chloro-N2-[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 845812-97-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(4-morpholinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845813-01-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-05-0 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845813-08-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-19-6 CAPLUS

CN Benzamide, 2-[5-chloro-2-[2-methoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845813-20-9 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845813-24-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-25-4 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-29-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-40-3 CAPLUS

CN Methanone, [4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinyl- (CA INDEX NAME)




RN 845813-66-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl]-2-(cyclopropylmethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845813-67-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(cyclopropylmethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)



RN 845813-71-0 CAPLUS


CN Methanone, [1,4'-bipiperidin]-1'-yl[4-[[5-chloro-4-[[2-[(1-

methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-
(CA INDEX NAME)




RN 845813-75-4 CAPLUS

CN Methanone, [4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 845813-76-5 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[4-[[5-chloro-4-[[2-(cyclohexylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)



RN 845814-12-2 CAPLUS


CN Methanone, [4-[[5-chloro-4-[[2-(cyclohexylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinyl- (CA INDEX NAME)



RN 845814-14-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-16-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-22-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-25-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845814-26-8 CAPLUS

CN Methanone, [4-[[5-chloro-4-[[2-(cyclohexylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-4-morpholinyl- (CA INDEX NAME)



RN 845814-43-9 CAPLUS


CN Benzamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845814-44-0 CAPLUS


CN Benzamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-

N-ethyl- (CA INDEX NAME)




RN 845814-45-1 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-46-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-51-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-methylphenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-52-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-53-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-54-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-80-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-ethoxy-4-(4-morpholinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 845814-82-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-3-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-N4-[2-[(2-methylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845814-83-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-3-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]-N4-[2-[(2-methylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845814-84-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-3-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]-N4-[2-(ethylsulfonyl)phenyl]- (CA INDEX NAME)



RN 845814-90-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[3-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]-N4-[2-[(2-methylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-91-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[3-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]-N4-[2-[(2-methylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 845814-99-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 845815-01-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl-2-(trifluoromethyl)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)



RN 845815-04-5 CAPLUS


CN Benzanide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(
 (trifluoromethyl)phenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA
 INDEX NAME)



RN 845815-05-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(trifluoromethyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-07-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-08-9 CAPLUS

CN Benzonitrile, 2-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-10-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-cyano-4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845815-11-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl-2-(2,2,2-trifluoroethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



IT 845815-12-5P 845815-13-6P 845815-18-1P

845815-19-2P 845815-20-5P 845815-29-4P

845815-30-7P 845815-31-8P 845815-36-3P

845815-37-4P 845815-38-5P 845815-39-6P

845815-40-9P 845815-41-0P 845815-46-5P

845815-47-6P 845815-48-7P 845815-49-8P


845815-62-5P 845815-63-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)


RN 845815-12-5 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-(2,2,2-trifluoroethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845815-13-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845815-18-1 CAPLUS

CN 2-Pyrrolidinone, 1-[1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]-4-piperidinyl]- (CA INDEX NAME)




RN 845815-19-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845815-20-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845815-29-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methyl-6-(4-morpholinyl)-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845815-30-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-[4-(dimethylamino)-1-piperidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845815-31-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 845815-36-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[2-methyl-6-(4-morpholinyl)-3-pyridinyl]- (CA INDEX NAME)




RN 845815-37-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[4-(dimethylamino)-1-piperidinyl]-2-(1-methylethoxy)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 845815-38-5 CAPLUS

CN Benzamide, 2-[[2-[(6-[1,4'-bipiperidin]-1'-yl-2-methyl-3-pyridinyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845815-39-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[6-[4-(dimethylamino)-1-piperidinyl]-2-methyl-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845815-40-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[6-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methyl-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-41-0 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[6-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-methyl-3-pyridinyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845815-46-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(6-[1,4'-bipiperidin]-1'-yl)-2-methyl-3-pyridinyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845815-47-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-(6-[4-(dimethylamino)-1-piperidinyl]-2-methyl-3-pyridinyl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845815-48-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[6-[(3S)-3-(dimethylethyl)sulfonyl]phenyl]-pyrrolidinyl-2-methyl-3-pyridinyl-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 845815-49-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[6-[(3R)-3-(dimethylethyl)sulfonyl]phenyl]-pyrrolidinyl-2-methyl-3-pyridinyl-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 845815-62-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)



RN 845815-63-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-[(1,4'-bipiperidin)-1'-yl]-2-methoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:158646 CAPLUS
 DN 142:254587
 TI Methods for treating or preventing autoimmune diseases with
 2,4-pyrimidinediamine compounds
 IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;
 Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger
 PA Rigel Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 276 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016893	A2	20050224	WO 2004-US24716	20040730
	WO 2005016893	A3	20050609		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004265288	A1	20050224	AU 2004-265288	20040730
	CA 2533377	A1	20050224	CA 2004-2533377	20040730
	US 20050209224	A1	20050922	US 2004-903870	20040730
	US 7122542	B2	20061017		
	US 20050234049	A1	20051020	US 2004-903263	20040730
	EP 1656372	A2	20060517	EP 2004-786150	20040730
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004013018	A	20061003	BR 2004-13018	20040730
	CN 1849318	A	20061018	CN 2004-80022235	20040730
	JP 2007500722	T	20070118	JP 2006-522105	20040730
	SG 145698	A1	20080929	SG 2008-5659	20040730
	RU 2356901	C2	20090527	RU 2006-106180	20040730
	NZ 545270	A	20100430	NZ 2004-545270	20040730
	KR 2006056353	A	20060524	KR 2006-701947	20060127
	MX 2006001099	A	20060920	MX 2006-1099	20060127
	IN 2006KN00449	A	20070622	IN 2006-KN449	20060227
	NO 2006000992	A	20060228	NO 2006-992	20060228
	US 20070167439	A1	20070719	US 2006-539147	20061005
	US 7452879	B2	20081118		
	US 20080312438	A1	20081218	US 2006-539142	20061005
	US 7582648	B2	20090901		
	US 20070225495	A1	20070927	US 2006-539520	20061006
	US 7560466	B2	20090714		
	US 20090318687	A1	20091224	US 2009-487486	20090618
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
	US 2004-903263	A1	20040730		

US 2004-903870 A1 20040730
 WO 2004-US24716 W 20040730
 US 2006-539520 A1 20061006

OS MARPAT 142:254587

AB The invention provides methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compds. include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosus and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.


IT 844434-19-1P 844434-20-4P 844434-21-5P
 845817-88-1P 845817-89-2P 845817-90-5P
 845817-93-8P 845820-86-2P 845820-87-3P
 845820-88-4P 845820-90-8P 845820-91-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrimidinediamine compds. for treatment or prevention of autoimmune diseases)


RN 844434-19-1 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-20-4 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethylphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-21-5 CAPLUS

CN Benzamide, 2-chloro-4-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-88-1 CAPLUS

CN Benamide, 2-chloro-5-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-89-2 CAPLUS

CN Benamide, 2-chloro-5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-90-5 CAPLUS

CN Benzamide, 2-chloro-4-[[4-[[4-chloro-3-[(methylamino)carbonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-93-8 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[[4-chloro-3-[(methylamino)carbonyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845820-86-2 CAPLUS

CN Glycine, N-[4-([5-fluoro-2-([3-(hydroxymethyl)phenyl)amino]-4-pyrimidinyl)amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-87-3 CAPLUS

CN Glycine, N-[4-([2-([3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-4-pyrimidinyl)amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-88-4 CAPLUS

CN Glycine, N-[4-([2-([3-chloro-4-hydroxyphenyl)amino]-5-fluoro-4-pyrimidinyl)amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-90-8 CAPLUS

CN Glycine, N,N'-[(5-fluoro-2,4-pyrimidinediyl)bis(imino-4,1-phenylenecarbonyl)]bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 845820-91-9 CAPLUS

CN Glycine, N-[4-[2-[[4-(aminocarbonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]aminobenzoyl]-, methyl ester (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/568,367 (RCE)

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:136565 CAPLUS
 DN 142:212327
 TI 2,4-pyrimidinediamine compounds and uses as antiproliferative agents
 IN Argade, Ankush; Singh, Rajinder; Li, Hui; Carroll, David; Catalano, Susan
 PA Rigel Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 179 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013996	A2	20050217	WO 2004-US25409	20040806
	WO 2005013996	A3	20050609		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050113398	A1	20050526	US 2004-913270	20040806
	EP 1663242	A2	20060607	EP 2004-780274	20040806
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	JP 2007501793	T	20070201	JP 2006-522744	20040806
	US 20070299060	A1	20071227	US 2006-567506	20061206
	US 20080009484	A1	20080110	US 2006-567824	20061207
	US 20080021020	A1	20080124	US 2006-567817	20061207
	US 20080027045	A1	20080131	US 2006-567820	20061207
PRAI	US 2003-494008P	P	20030807		
	US 2004-572534P	P	20040518		
	US 2004-572507P	P	20040518		
	US 2004-580765P	P	20040618		
	US 2004-913270	A1	20040806		
	WO 2004-US25409	W	20040806		
	US 2004-628199P	P	20041115		
	US 2004-628496P	P	20041115		
	US 2005-650195P	P	20050203		
	US 2005-133419	A1	20050518		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 142:212327

AB The invention provides 2,4-pyrimidinediamine compds. having antiproliferative activity, compns. comprising the compds. and methods of using the compds. to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.

IT 844434-19-1P 844434-20-4P 844434-21-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pyrimidinediamine compds. and uses as antiproliferative agents for treatment of cancer)


RN 844434-19-1 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-20-4 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethylphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 844434-21-5 CAPLUS

CN Benzamide, 2-chloro-4-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/568,367 (RCE)

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:780679 CAPLUS
 DN 141:296041
 TI Preparation of novel 2,4-di(phenylamino)pyrimidines useful in the
 treatment of neoplastic diseases, inflammatory and immune system disorders
 IN Garcia-Echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya,
 Keiichi; Matsura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 185 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080980	A1	20040923	WO 2004-EP2616	20040312
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004220338	A1	20040923	AU 2004-220338	20040312
	AU 2004220338	B2	20081009		
	CA 2518932	A1	20040923	CA 2004-2518932	20040312
	EP 1606265	A1	20051221	EP 2004-719989	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008347	A	20060321	BR 2004-8347	20040312
	CN 1788001	A	20060614	CN 2004-80013041	20040312
	JP 2006520354	T	20060907	JP 2006-504673	20040312
	NZ 542219	A	20090131	NZ 2004-542219	20040312
	ZA 2005006751	A	20070228	ZA 2005-6751	20050823
	IN 2005CN02241	A	20070831	IN 2005-CN2241	20050913
	NO 2005004726	A	20051208	NO 2005-4726	20051013
	US 20060247241	A1	20061102	US 2006-549250	20060518
	IN 2009CN00759	A	20090605	IN 2009-CN759	20090209
PRAI	GB 2003-5929	A	20030314		
	GB 2003-19227	A	20030815		
	GB 2003-22370	A	20030924		
	WO 2004-EP2616	A	20040312		
	IN 2005-CN2241	A3	20050913		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:296041

AB The title pyrimidine derivs. I [R0-R3 = H, alkyl, aryl, etc.; or R0 and R1, R1 and R2, and/or R2 and R3 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, halo, etc.; R7-R10 = alkyl, cycloalkyl, aryl, etc.; or R7 and R8, R8 and R9, and/or R9 and R10 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; A =

TD filed
(approved)

copending

C, NJ, useful as FAK or/and IGF-1 receptor inhibitors in the treatment of neoplastic diseases, inflammatory and immune system disorders, were prepared and formulated. E.g., a 2-step synthesis of II from 2,4-dichloro-5-nitropyrimidine, 2-amino-N-methylbenzenesulfonamide, and 2,5-dimethoxyaniline which showed IC50 of 140 nM in FAK assay, was given. The pharmaceutical composition comprising the compound I is claimed.

IT	761437-28-9P	761437-29-0P	761437-30-3P
	761437-31-4P	761437-32-5P	761437-33-6P
	761437-34-7P	761437-35-8P	761437-36-9P
	761437-37-0P	761437-39-2P	761437-40-5P
	761437-41-6P	761437-42-7P	761437-43-8P
	761437-44-9P	761437-45-0P	761437-46-1P
	761437-47-2P	761437-48-3P	761437-49-4P
	761437-50-7P	761437-51-8P	761437-52-9P
	761437-53-0P	761437-54-1P	761437-55-2P
	761437-59-6P	761437-60-9P	761437-61-0P
	761437-62-1P	761437-63-2P	761437-64-3P
	761437-65-4P	761437-66-5P	761437-67-6P
	761437-68-7P	761437-69-8P	761437-70-1P
	761437-71-2P	761437-72-3P	761437-73-4P
	761437-74-5P	761437-76-7P	761437-84-7P
	761437-85-8P	761437-86-9P	761437-88-1P
	761437-91-6P	761437-92-7P	761437-93-8P
	761437-94-9P	761437-95-0P	761437-96-1P
	761437-97-2P	761438-00-0P	761438-89-5P
	761438-90-8P	761438-91-9P	761438-92-0P
	761438-93-1P	761438-95-3P	761438-96-4P
	761438-97-5P	761438-98-6P	761438-99-7P
	761439-00-3P	761439-01-4P	761439-02-5P
	761439-03-6P	761439-04-7P	761439-05-8P
	761439-06-9P	761439-07-0P	761439-08-1P
	761439-09-2P	761439-10-5P	761439-11-6P
	761439-12-7P	761439-13-8P	761439-14-9P
	761439-15-0P	761439-16-1P	761439-17-2P
	761439-18-3P	761439-19-4P	761439-20-7P
	761439-21-8P	761439-22-9P	761439-23-0P
	761439-24-1P	761439-25-2P	761439-26-3P
	761439-27-4P	761439-28-5P	761439-29-6P
	761439-30-9P	761439-31-0P	761439-32-1P
	761439-33-2P	761439-34-3P	761439-35-4P
	761439-36-5P	761439-37-6P	761439-38-7P
	761439-39-8P	761439-40-1P	761439-41-2P
	761439-42-3P	761439-43-4P	761439-44-5P
	761439-45-6P	761439-46-7P	761439-47-8P
	761439-48-9P	761439-49-0P	761439-50-3P
	761439-51-4P	761439-52-5P	761439-53-6P
	761439-54-7P	761439-55-8P	761439-56-9P
	761439-57-0P	761439-58-1P	761439-59-2P
	761439-60-5P	761439-61-6P	761439-62-7P
	761439-63-8P	761439-64-9P	761439-65-0P
	761439-66-1P	761439-67-2P	761439-81-0P
	761439-82-1P	761439-85-4P	761439-86-5P
	761439-94-5P	761439-95-6P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor

inhibitors useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)


RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-29-0 CAPLUS

CN Benzamide, 2-[[2-[[4-(1,4'-bipiperidin)-1'-yl-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-30-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761437-31-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-32-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(2-(4-morpholinyl)ethoxy]phenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-33-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-34-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-35-8 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-36-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-37-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(2-ethoxyethoxy)-1-piperidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-39-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(2-methoxyethoxy)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-40-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-42-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761437-43-8 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-44-9 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-45-0 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[4-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-46-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-47-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761437-48-3 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-49-4 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-50-7 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-51-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-52-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-53-0 CAPLUS


CN Benzamide, 2-[[2-[[5-(1,4'-bipiperidin-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-54-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-59-6 CAPLUS

CN Benamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-60-9 CAPLUS

CN Benamide, 2-[[2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-61-0 CAPLUS

CN Benamide, 2-[[2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-62-1 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-63-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-64-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-65-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-66-5 CAPLUS


CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-67-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 761437-68-7 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-69-8 CAPLUS
 CN Benzamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-

chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-70-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-71-2 CAPLUS

CN Benzamide, 2-[[2-[[4-[(1,4'-bipiperidin)-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-72-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-73-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-74-5 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-bipiperidin-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-76-7 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 761437-85-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761437-86-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 761437-88-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-5-fluoro- (CA INDEX NAME)




RN 761437-91-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 761437-92-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 761437-93-8 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 761437-94-9 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)



RN 761437-95-0 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)-

pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 761437-96-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-5-methoxy-N-methyl- (CA INDEX NAME)



RN 761437-97-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-00-0 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


10/568,367 (RCE)

chloro-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)




RN 761438-89-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761438-90-8 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761438-91-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761438-92-0 CAPLUS

CN 4-Piperidinol, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-93-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-95-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N-methyl- (CA INDEX NAME)




RN 761438-96-4 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-2,6-dimethyl-1-piperazinyl]- (CA INDEX NAME)




RN 761438-97-5 CAPLUS

CN 1-Propanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761438-98-6 CAPLUS

CN 1-Propanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)




RN 761438-99-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N-methyl- (CA INDEX NAME)



RN 761439-00-3 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-2,2-dimethyl-1-piperazinyl- (CA INDEX NAME)



RN 761439-01-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761439-02-5 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761439-03-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-04-7 CAPLUS

CN Ethanone, 1-[4-[3-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-05-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[[2-(4-morpholinyl)ethyl]amino]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-06-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-(4-morpholinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-07-0 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenoxy]ethyl]- (CA INDEX NAME)




RN 761439-08-1 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxybenzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-09-2 CAPLUS

CN Methanone, [4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinyl- (CA INDEX NAME)




RN 761439-10-5 CAPLUS

CN 1-Piperazineacetamide, 4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761439-11-6 CAPLUS

CN 2-Piperazinone, 4-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-12-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-13-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-14-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-15-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-16-1 CAPLUS

CN 4-Piperidinemethanol, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-17-2 CAPLUS

CN 3-Pyrrolidinol, 1-[4-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-18-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-19-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(4-fluoro-2-methoxyphenyl)-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-20-7 CAPLUS

CN Ethanone, 1-[4-[2-[3-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenoxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-21-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-22-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-23-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-24-1 CAPLUS

CN 4-Piperidinol, 1-[3-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenyl]- (CA INDEX NAME)




RN 761439-25-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-26-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-27-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-28-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-[[5-chloro-4-[[2-(propylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-methoxyphenyl]- (CA INDEX NAME)




RN 761439-29-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 761439-30-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl)-5-chloro-N4-[2-(ethylsulfonyl)phenyl]- (CA INDEX NAME)




RN 761439-31-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]- (CA INDEX NAME)




RN 761439-32-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 761439-33-2 CAPLUS

CN Ethanone, 1-[4-[4-[5-chloro-4-[[2-(ethylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-34-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[5-chloro-4-[[2-(ethylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761439-35-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)



RN 761439-36-5 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(ethylsulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 761439-37-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(ethylsulfonyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 761439-38-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-
(CA INDEX NAME)




RN 761439-39-8 CAPLUS

CN 1-Piperazineethanol, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-40-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-41-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-42-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-

piperazinyl]-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
(CA INDEX NAME)




RN 761439-43-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[2-methyl-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 761439-44-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(2-methoxy-4-nitrophenyl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-45-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-46-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-47-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(methoxymethyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-48-9 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-49-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-(4-ethyl-1-piperazinyl)-2-methoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-50-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-51-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-52-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-53-6 CAPLUS

CN 4-Piperidinol, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761439-54-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(3-methoxy-1-pyrrolidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-55-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-methoxy-1-piperidinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-56-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-57-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(methylamino)-1-piperidinyl]oxy]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-58-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-59-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-60-5 CAPLUS

CN 2-Piperazinone, 4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-methyl- (CA INDEX NAME)




RN 761439-61-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-62-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-{4-(1-piperazinyl)-1-piperidinyl}phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-63-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[4-{(9aS)-hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-2-yl]-2-methoxyphenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 761439-64-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761439-65-0 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761439-66-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-5-(4-morpholinyl)phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 761439-67-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-(2,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 761439-81-0 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[[2-[(2-methylpropyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 761439-82-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]-N4-[2-[(2-methylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-85-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[2-(butylsulfonyl)phenyl]-5-chloro-N2-[2-methoxy-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 761439-86-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(cyclohexylsulfonyl)phenyl]-N2-[2-

methoxy-4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 761439-94-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(4-fluoro-2-methoxyphenyl)-N4-(4-methyl-1-piperazinyl)-2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-95-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L9 ANSWER 52 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:675730 CAPLUS
DN 141:207218
TI Pyrimidine derivatives for the prevention of HIV infection
IN Janssen, Paul Adriaan Jan; Heeres, Jan; Lewi, Paulus Joannes; De Jonge,
Marc Rene; Koymans, Lucien Maria Henricus; Daeyaert, Frederik Frans
Desire; Vinkers, Hendrik Maarten
PA Janssen Pharmaceutica N.V., Belg.; Arts, Theodora Joanna Francisca;
Janssen, Graziella Maria Constantina; Janssen, Herwig Josephus Margareta;
Janssen, Jasmine Josee Werner; Janssen, Paul Peter Maria; Janssen,
Maroussia Godelieve Frank; Guillemont, Jerome Emile Georges; Pasquier,
Elisabeth Therese Jeanne
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAM.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004069812	A1	20040819	WO 2004-EP1011	20040204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LU, LK, LR, LS, LT, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NH, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SY, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW, ZY				
	RW: BG, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BW, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004210081	A1	20040819	AU 2004-210081	20040204
	AU 2004210081	B2	20091126		
	CA 2513527	A1	20040819	CA 2004-2513527	20040204
	EP 1597237	A1	20051123	EP 2004-707937	20040204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007329	A	20060110	BR 2004-7329	20040204
	CN 1747937	A	20060315	CN 2004-80003460	20040204
	JP 2006516591	T	20060706	JP 2006-501729	20040204
	NZ 541902	A	20081224	NZ 2004-541902	20040204
	AP 2065	A	20091231	AP 2005-3366	20040204
	IN 2005DN02821	A	20070316	IN 2005-DN2821	20050624
	HR 2005000688	A2	20060831	HR 2005-688	20050801
	ZA 2005006253	A	20080528	ZA 2005-6253	20050804
	NO 2005004143	A	20050906	NO 2005-4143	20050906
	US 20070021449	A1	20070125	US 2006-544735	20060926
	US 20100034810	A1	20100211	US 2009-567051	20090925
PRAI	WO 2003-EP1291	A	20030207		
	WO 2004-EP1011	A	20040204		
	US 2006-544735	A1	20060926		
OS	MARPAT 141:207218				

AB This invention concerns the use of a compound I [a:1a2:3a:4a,b1:2b3:b4 = atoms to form Ph, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl rings; n = 0-5; m = 1-4; R1 = H, aryl, CHO, alkylcarbonyl, alkyl, alkyloxy,alkylcarbonyl, alkylcarbonyl, etc.; R2 = O, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, carboxyl, CN, NO2, NH2, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, SOpR6, NHSOpR6, COR6, NHCOH, CONHNH2, NHCORe, C:(NH)R6, 5-membered heterocycle; X1 = NR5, NNNH, N:N, O, CO, alkanediyl, CH(OH), S, SOp, X2-alkanediyl, alkanediyl-X2; X2 =


NR5, NHHH, N:N, O, CO, CH(OH), S, SOp; R3 = NHR13, NR13R14, CONHR13, CONR13R14, COR15, CH:NNHCOR16, substituted alkyl, (substituted) alkoxyalkyl, substituted alkenyl, alkynyl, alkyl substituted with OH and a second substituent, C(:NOR8)-alkyl, R7, X3R7; R4 = halo, OH, alkyl, cycloalkyl, alkoxy, CN, NO2, polyhaloalkyl, polyhaloalkoxy, aminocarbonyl, alkyloxycarbonyl, alkylcarbonyl, CHO, NH2; R5 = H, aryl, CHO, alkylcarbonyl, alkyl, alkoxy, carbonyl, etc.; R6 = alkyl, amino, polyhaloalkyl; R7 = mono-, bi-, or tricyclic (aromatic) carbocyclyl, heterocyclyl; R13, R14 = alkyl, alkenyl, alkynyl optionally substituted by cyano, aminocarbonyl; R15 = cyanoalkyl, aminocarbonylalkyl; R16 = R15, R7; p = 1, 2] for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, and pharmaceutical compns. comprising them. Preparation of compds. I is disclosed and described in WO 2003/016306. A 2-step synthesis of novel compound I, (E)-4-[(4-[(2-cyanoethyl)-2,6-dimethylphenoxy]-2-pyrimidinyl)amino]benzonitrile, starting from 4-hydroxy-3,5-dimethylbenzaldehyde and 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile, which showed PIC50 of 9.00 when tested for anti-HIV properties, was given.

IT 500288-32-4 500290-33-5 500290-35-7
500290-37-9 500290-39-1 500290-41-5
500290-43-7 500290-49-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrimidine derivs. for the prevention of HIV infection)

RN 500288-32-4 CAPLUS


CN Benamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)



at least 2 differences:
- the phenyl at 2- of pyrimidine contains 2 ring subs
- the phenyl at 4- of pyrimidine contains -CO-NH-ethyl and no methyl on the ring


RN 500290-33-5 CAPLUS

CN Benamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N,3,5-tetramethyl- (CA INDEX NAME)




RN 500290-35-7 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-37-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N-diethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-39-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-41-5 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 500290-43-7 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)



RN 500290-49-3 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



OSC.G	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 53 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:486399 CAPLUS
 DN 141:54353
 TI Pharmaceutical compositions comprising a surfactant and a physiologically
 tolerable water-soluble acid respectively base, and a basic respectively
 acidic drug compound, containing a pyrimidine unit, for treating HIV
 IN Vandercruys, Roger Petrus Gerebern
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050068	A1	20040617	WO 2002-EP13558	20021129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002350719	A1	20040623	AU 2002-350719	20021129
	CA 2505742	A1	20040617	CA 2003-2505742	20031125
	WO 2004050058	A2	20040617	WO 2003-EP50890	20031125
	WO 2004050058	A3	20040930		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003294038	A1	20040623	AU 2003-294038	20031125
	AU 2003294038	B2	20090611		
	EP 1567134	A2	20050831	EP 2003-789453	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016532	A	20051004	BR 2003-16532	20031125
	CN 1720027	A	20060111	CN 2003-80104619	20031125
	JP 2006514635	T	20060511	JP 2004-556332	20031125
	NZ 540846	A	20080328	NZ 2003-540846	20031125
	AP 2100	A	20100228	AP 2005-3318	20031125
	HR 2005000458	A2	20051031	HR 2005-458	20050524
	IN 2005DN02185	A	20070302	IN 2005-DN2185	20050524
	US 20060078609	A1	20060413	US 2005-536542	20050526
	ZA 2005004312	A	20060726	ZA 2005-4312	20050526
	MX 2005005709	A	20050816	MX 2005-5709	20050527
	NO 2005003143	A	20050627	NO 2005-3143	20050627
PRAI	WO 2002-EP13558	A	20021129		

WO 2003-EP50890 W 20031125

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides a novel pharmaceutical composition for treating HIV comprising a basic resp. acidic drug compound I, a surfactant and a physiologically tolerable water-soluble acid resp. base in which the acid resp. base:drug compound ratio is at least 1:1 by weight [wherein X = O, NH; Y = NH, NMe; R1 = Me, H; R2 = Me, Cl, Br, OMe, 2-furanyl, etc.; R3 = H, 2-benzofuranyl, 1-naphthalenyl, (un)substituted Ph, CH2CH2CN, CH:CHCN, etc.; R4 = H, NO2, NH2, etc.; their N-oxides, pharmaceutically acceptable addition salts, quaternary amines, or stereochem. isomeric forms]. Ten pharmaceutical compns. are given. Thus, amination of 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (preparation given) with amine II (preparation given) in the presence of K2CO3/CH2Cl2/MeOH at 150° for 1 h gave the title compound III. Selected I displayed pIC50 values in the range 8.0-9.5 for the inhibition of the HIV-induced cytopathic effect.


IT 500288-32-4P 500290-33-5P 500290-35-7P
 500290-37-9P 500290-39-1P 500290-41-5P
 500290-43-7P 500290-49-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-HIV agent; preparation of pyrimidine-based anti-HIV agents and their pharmaceutical compns.)


RN 500288-32-4 CAPLUS

CN Benamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-33-5 CAPLUS

CN Benamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N,3,5-tetramethyl- (CA INDEX NAME)




RN 500290-35-7 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-37-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N-diethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-39-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-41-5 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 500290-43-7 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)



RN 500290-49-3 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



OSC.G	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT	10	THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 54 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2004:142963 CAPLUS
 DN 140:199334
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor
 modulators for treatment of autoimmune diseases
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim,
 Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar
 PA Rigel Pharmaceuticals, USA
 SO PCT Int. Appl., 811 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492325	A1	20040219	CA 2003-2492325	20030729
	AU 2003265336	A1	20040225	AU 2003-265336	20030729
	AU 2003265336	B2	20080619		
	EP 1534286	A1	20050601	EP 2003-784871	20030729
	EP 1534286	B1	20091209		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013059	A	20050705	BR 2003-13059	20030729
	JP 2006514989	T	20060518	JP 2005-506142	20030729
	NZ 537752	A	20061222	NZ 2003-537752	20030729
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	US 7517886	B2	20090414	US 2003-631029	20030729
	US 20070060603	A1	20070315		
	AT 451104	T	20091215	AT 2003-784871	20030729
	RU 2376992	C2	20091227	RU 2005-105344	20030729
	HR 2005000089	A2	20070831	HR 2005-89	20050126
	SE 2005000203	A	20050329	SE 2005-203	20050127
	NO 2005001069	A	20050228	NO 2005-1069	20050228
	IN 2005KN00302	A	20060421	IN 2005-KN302	20050228
	HK 1079978	A1	20100723	HK 2005-110991	20051201
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	IN 2007KN02546	A	20070824	IN 2007-KN2546	20070709
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		
	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 7655797	B2	20100202		
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
	US 20100197918	A1	20100805	US 2010-762178	20100416
PRAI	US 2002-399673P	P	20020729		

US	2003-443949P	P	20030131
US	2003-452339P	P	20030306
US	2003-631029	A	20030729
US	2002-353267P	P	20020201
US	2002-353333P	P	20020201
US	2002-434277P	P	20021217
AU	2003-208931	A3	20030131
US	2003-355543	A1	20030131
WO	2003-US24087	W	20030729
US	2004-858343	A3	20040601
IN	2005-KN302	A3	20050228
US	2005-149418	A1	20050608
US	2006-539041	A1	20061005
US	2006-539049	A1	20061005
US	2006-539054	A3	20061005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 140:199334; MARPAT 140:199334

AB The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).


IT	575484-59-2P	575484-65-0P	662227-39-6P
	662227-46-5P	662227-55-6P	662227-67-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)


RN 575484-59-2 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)




RN 575484-65-0 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-(1-methylethyl)- (CA INDEX NAME)




RN 662227-39-6 CAPLUS

CN Benzamide, N-(2-aminoethyl)-5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 662227-46-5 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 662227-55-6 CAPLUS


CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylamino)ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 662227-67-0 CAPLUS

CN Benzamide, N-[(2R)-2,3-dihydroxypropyl]-5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:610204 CAPLUS
 DN 139:164801
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor
 modulators for treatment of allergic diseases, inflammatory conditions,
 and tissue destruction
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan;
 Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekar;
 Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.
 PA Rigel Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 648 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063794	A2	20030807	WO 2003-US3022	20030131
	WO 2003063794	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474277	A1	20030807	CA 2003-2474277	20030131
	EP 1471915	A2	20041103	EP 2003-707654	20030131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005516046	T	20050602	JP 2003-563490	20030131
	CN 1625400	A	20050608	CN 2003-803180	20030131
	BR 2003007355	A	20060411	BR 2003-7355	20030131
	NZ 534361	A	20080430	NZ 2003-534361	20030131
	AU 2003208931	B2	20080904	AU 2003-208931	20030131
	RU 2343148	C2	20090110	RU 2004-126431	20030131
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	HR 2004000684	A2	20081231	HR 2004-684	20040723
	ZA 2004005979	A	20070425	ZA 2004-5979	20040727
	MX 2004007386	A	20060427	MX 2004-7386	20040730
	IN 2004KN01139	A	20060512	IN 2004-KN1139	20040809
	IN 239514	A1	20100326		
	NO 2004003632	A	20041026	NO 2004-3632	20040831
	NO 328071	B1	20091123		
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		
	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 7655797	B2	20100202		
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
	US 20100197918	A1	20100805	US 2010-762178	20100416
PRAI	US 2002-353267P	P	20020201		

US 2002-353333P	P	20020201
US 2002-399673P	P	20020729
US 2002-434277P	P	20021217
AU 2003-208931	A3	20030131
US 2003-355543	A1	20030131
WO 2003-US3022	W	20030131
US 2004-058343	A3	20040601
US 2005-149418	A1	20050608
US 2006-539041	A1	20061005
US 2006-539049	A1	20061005
US 2006-539054	A3	20061005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:164801

AB Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. The treatment and prevention of allergic diseases, low grade scarring, diseases associated with tissue destruction, diseases associated with tissue inflammation, inflammation, and scarring are targeted uses (no data).


IT 575484-59-2P 575484-65-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)


RN 575484-59-2 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)



RN 575484-65-0 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-(1-methylethyl)- (CA INDEX NAME)



OSC.G 37 THERE ARE 37 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)

L9 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2003:154426 CAPLUS
 DN 138:205077
 TI Preparation of pyrimidines as HIV inhibitors.
 IN Guilleumont, Jerome Emile Georges; Palandjian, Patrice; De Jonge, Marc
 Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Daeyaert,
 Frederik Frans Desire; Heeres, Jan; Van Aken, Koen Jeanne Alfons; Lewi,
 Paulus Joannes; Janssen, Paul Adriaan Jan
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016306	A1	20030227	WO 2002-EP8953	20020809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2452217	A1	20030227	CA 2002-2452217	20020809
	CA 2452217	C	20090616		
	AU 2002329238	A1	20030303	AU 2002-329238	20020809
	AU 2002329238	B2	20080124		
	EP 1419152	A1	20040519	EP 2002-764839	20020809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011909	A	20040824	BR 2002-11909	20020809
	CN 1541215	A	20041027	CN 2002-815920	20020809
	CN 100509801	C	20090708		
	HU 2004001346	A2	20041228	HU 2004-1346	20020809
	HU 2004001346	A3	20090302		
	JP 2005507380	T	20050317	JP 2003-521229	20020809
	NZ 530951	A	20051028	NZ 2002-530951	20020809
	AP 1610	A	20060630	AP 2004-2993	20020809
	CN 101816658	A	20100901	CN 2009-10145401	20020809
	EG 24684	A	20100505	EG 2002-892	20020810
	TW 272945	B	20070211	TW 2002-91118061	20020812
	TW 315199	B	20091001	TW 2006-95115978	20020812
	KR 817453	B1	20080327	KR 2004-7000372	20040109
	HR 2004000096	A2	20040630	HR 2004-96	20040129
	US 20040198739	A1	20041007	US 2004-485636	20040203
	US 7125879	B2	20061024		
	IN 2004DN00265	A	20050401	IN 2004-DN265	20040206
	IN 222987	A1	20080912		
	NO 2004000633	A	20040312	NO 2004-633	20040212
	NO 327639	B1	20090907		
	ZA 2004001159	A	20050512	ZA 2004-1159	20040212
	MX 2004001401	A	20040527	MX 2004-1401	20040213
	HK 1070066	A1	20100409	HK 2005-102760	20050401

	US 20060111379	A1	20060525	US 2005-219163	20050902
	US 7638522	B2	20091229		
	US 20060252764	A1	20061109	US 2006-474855	20060626
	KR 2007101409	A	20071016	KR 2007-7022611	20071002
	KR 969273	B1	20100820		
	IN 2008DN00715	A	20080711	IN 2008-DN715	20080125
	US 20090012108	A1	20090108	US 2008-168540	20080707
	NO 2008003770	A	20040312	NO 2008-3770	20080902
	JP 2010077140	A	20100408	JP 2009-259107	20091112
PRAI	EP 2001-203090	A	20010813		
	EP 2002-77748	A	20020610		
	CN 2002-815920	A3	20020809		
	JP 2003-521229	A3	20020809		
	WO 2002-EP8953	W	20020809		
	EP 2003-103275	A	20030903		
	US 2003-499771P	P	20030903		
	EP 2003-103319	A	20030908		
	EP 2003-103335	A	20030910		
	EP 2003-103668	A	20031002		
	US 2003-508486P	P	20031003		
	KR 2004-700372	A3	20040109		
	US 2004-485636	A2	20040203		
	IN 2004-DN265	A3	20040206		
	MY 2004-3578	A	20040902		
	WO 2004-EP52028	A	20040903		
	EP 2005-101467	A	20050225		
	US 2005-219163	A1	20050902		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 138:205077

AB Title compds. [I; al:a2a3:a4, b1:b2b3:b4 = atoms to form Ph, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl rings; n = 0-5; m = 1-4; R1 = H, aryl, CHO, alkylcarbonyl, alkyl, alkyloxy, carbonyl, substituted alkyl, alkylcarbonyl; R2 = OH, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxy, carbonyl, carboxyl, cyano, NO2, amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, SOpR6, NHSOpR6, COR6, NHCOR6, CONHNH2, NHCOR6, C(NH)R6, 5-membered heterocycle; X1 = NR5, NNNH, N:N, O, CO, alkanediyl, CH(OH), S, SOp, X2-alkanediyl, alkanediyl-X2; X2 = NR5, NNNH, N:N, O, CO, CH(OH), S, SOp; R3 = NHR13, NR13R14, CONHR13, CONR13R14, COR15, CH:NNHCOR16, substituted alkyl, (substituted) alkoxyalkyl, substituted alkenyl, alkynyl, alkyl substituted with OH and a second substituent, C(NOR8)-alkyl, R7, X3R7; R4 = halo, OH, alkyl, cycloalkyl, alkoxy, cyano, nitro, polyhaloalkyl, polyhaloalkoxy, aminocarbonyl, alkyloxy, carbonyl, alkylcarbonyl, CHO, amino; R5 = H, aryl, CHO, alkylcarbonyl, alkyl, alkoxy, carbonyl, etc.; R6 = alkyl, amino, polyhaloalkyl; R7 = mono-, bi-, or tricyclic (aromatic) carbocyclyl, heterocyclyl; R13, R14 = alkyl, alkenyl, alkynyl optionally substituted by cyano, aminocarbonyl; R15 = cyanoalkyl, aminocarbonylalkyl; R16 = R15, R7; p = 1, 2], were prepared. Thus, 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (preparation given) and 4-(2-cyanoethenyl)-2,6-dimethylaniline were stirred together at 150° for 1 h to give 4-[[4-[(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile. The latter inhibited HIV-induced cytopathic effect in MT-4 cells with pIC50 = 9.4.


IT 500288-32-4P 500290-33-5P 500290-35-7P
500290-37-9P 500290-39-1P 500290-41-5P
500290-43-7P 500290-49-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidines as HIV inhibitors)


RN 500288-32-4 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-33-5 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N,3,5-tetramethyl- (CA INDEX NAME)




RN 500290-35-7 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-37-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N-diethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-39-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-41-5 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 500290-43-7 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)



RN 500290-49-3 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2000:161263 CAPLUS
 DN 132:194385
 TI Preparation of bis(arylamino)pyrimidine derivatives as anticancer agents
 IN Breault, Gloria Anne; Pease, Janet Elizabeth
 PA Zeneca Limited, UK
 SO PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012485	A1	20000309	WO 1999-GB2790	19990824
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RM: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9954382	A	20000321	AU 1999-54382	19990824
	EP 1107957	A1	20010620	EP 1999-940401	19990824
	EP 1107957	B1	20061018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	JP 2002523497	T	20020730	JP 2000-567515	19990824
	AT 342892	T	20061115	AT 1999-940401	19990824
	ES 2274634	T3	20070516	ES 1999-940401	19990824
	HK 1035531	A1	20070330	HK 2001-106036	20010827
	US 20050090493	A1	20050428	US 2004-771118	20040204
	US 7176212	B2	20070213		
PRAI	GB 1998-18989	A	19980829		
	GB 1998-28433	A	19981224		
	WO 1999-GB2790	W	19990824		
	US 2001-763705	B1	20010226		
OS	MARPAT 132:194385				
AB	<p>The title compds. (I) [wherein R1 = H or (un)substituted alkyl, alkenyl or alkynyl; Q1 and Q2 = independently (un)substituted Ph, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, and one or both of Q1 and Q2 is substituted with -X(CH2)nCHY(CH2)mZ; X = CH2, O, S, or NH; Y = H or as defined for Z; Z = OH, SH, NH2, alkoxy, alkylthio, (cyclo)alkylamino, or dialkylamino; n = 1-3; m = 1-3] were prepared as cyclin dependent kinase (CDK) and focal adhesion kinase (FAK) inhibitors. Examples include over 100 syntheses, descriptions of a number of biol. assays with some data, and 7 pharmaceutical formulations. For instance, 2-chloro-4-(2-bromo-4-methylanilino)pyrimidine (preparation given) was coupled with 4-[3-(N,N-dimethylamino)-2-hydroxypropoxy]aniline (preparation given) in BuOH to give II. The latter inhibited CDK4 with IC50 = 0.6 µM and FAK with IC50 = 3.3 µM. Typical IC50 values for compds. of the invention when tested in the Sulforhodamine B (SRB) cell growth inhibition assay were in the range of 1 mM to 1 nM. I and their pharmaceutically-acceptable salts and in-vivo-hydrolyzable esters are useful as anticancer agents, antiproliferatives, cell migration inhibitors, and apoptotic agents.</p>				
IT	260045-01-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological				

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of bis(arylamino)pyrimidine derivs. as anticancer agents, antiproliferatives, cell migration inhibitors, and apoptotic agents)

RN 260045-01-0 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-[[3-[(2-hydroxyethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)



OSC.G 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/568,367 (RCE)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

333.67

529.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY



SESSION

CA SUBSCRIBER PRICE

-48.45

-48.45

STN INTERNATIONAL LOGOFF AT 15:01:53 ON 20 SEP 2010



```

chain nodes :
  13 14 16 19 20 21 22 23 30 31 32 33 40
ring nodes :
  1 2 3 4 5 6 7 8 9 10 11 12 24 25 26 27 28 29
chain bonds :
  2-20 3-19 4-14 6-13 9-14 13-16 21-23 22-26 30-31 30-32 32-33
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 24-25 24-29 25-26 26-27
  27-28 28-29
exact/norm bonds :
  3-19 4-14 6-13 9-14 13-16 21-23 30-31 30-32 32-33
exact bonds :
  2-20 22-26 24-25 24-29 25-26 26-27 27-28 28-29
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
  containing 1 : 7 : 24 :

```

G1:H,Cl,Br,F,I

G2:[*1],[*2],[*3]

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
  12:Atom 13:CLASS 14:CLASS 16:Atom 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:Atom
  25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:CLASS 31:CLASS 32:CLASS 33:CLASS 40:CLASS
  41:Atom
Generic attributes :
  16:
  Saturation : Unsaturated
  Number of Carbon Atoms : less than 7
  Number of Hetero Atoms : 2 or more
  Type of Ring System : Monocyclic
  23:

```

Saturation : Saturated
Number of Carbon Atoms : less than 7
33:
Saturation : Saturated
Number of Carbon Atoms : less than 7

Element Count :

Node 16: Limited

C,C3

N,N2

O,O0

S,S0

Node 23: Limited


C,C2-4

Node 33: Limited

C,C1-3

=>

Uploading C:\Program Files\Stnexp\Queries\10568367 (RCE b).str



```

chain nodes :
13 14 16 19 20 21 22 23 30 31 32 33 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 24 25 26 27 28 29
chain bonds :
2-20 3-19 4-14 6-13 9-14 13-16 21-23 22-26 30-31 30-32 32-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 24-25 24-29
25-26 26-27 27-28 28-29
exact/norm bonds :
3-19 4-14 6-13 9-14 13-16 21-23 30-31 30-32 32-33

```

```

exact bonds :
2-20 22-26 24-25 24-29 25-26 26-27 27-28 28-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 : 24 :

```

G1:H,Cl,Br,F,I

G2:[*1],[*2],[*3]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 16:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:CLASS
31:CLASS 32:CLASS 33:CLASS 40:CLASS 41:Atom
Generic attributes :

```

```

16:
Saturation      : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic
23:
Saturation      : Saturated
Number of Carbon Atoms : less than 7
33:
Saturation      : Saturated
Number of Carbon Atoms : less than 7

```

Element Count :

```

Node 16: Limited
  C,C3
  N,N2
  O,O0
  S,S0

```

```

Node 23: Limited
  C,C2-4

```

```

Node 33: Limited
  C,C1-3

```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```

=> s l1 sss sam
SAMPLE SEARCH INITIATED 17:01:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      1215 TO ITERATE

100.0% PROCESSED      1215 ITERATIONS          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   22209 TO   26391
PROJECTED ANSWERS:      1 TO      80

L2          1 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 17:01:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      24798 TO ITERATE

100.0% PROCESSED      24798 ITERATIONS        3 ANSWERS
SEARCH TIME: 00.00.01

L3          3 SEA SSS FUL L1


=> => s l3
L4          2 L3

=> d l4 1-2 bib,ab,hitstr

```


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1450755 CAPLUS
 DN 150:20148
 TI Preparation of substituted 2-[(3-pyridylamino)-2-pyrimidinyl]anthranilamides as Aurora kinase inhibitors
 IN Axten, Jeffrey Michael; Betancourt, Jesus R. Medina; Johnson, Neil W.; Semones, Marcus
 PA SmithKline Beecham Corporation, USA
 SO PCT Int. Appl., 55pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008147831	A1	20081204	WO 2008-US64446	20080522
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2007-939624P	P	20070523		
OS CASREACT 150:20148; MARPAT 150:20148				
AB	Title compds. I (R1 = H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkylmethyl, C1-6 hydroxyalkyl; R2 = Me, F, Cl; R3 = nitrogen-containing 5- or 6-membered heterocycle), or pharmaceutically acceptable salts thereof, are prepared as Aurora kinase inhibitors. Thus, reaction of 2,4-dibromo-5-methylpyrimidine with 2-amino-N-isopropylbenzamide, followed by further reaction with 6-(4-methyl-2-piperazinyl)-3-pyridinamine gave title compd II, isolated as the HCl salt. The prepared compds. were tested for Aurora A/TPX12 and Aurora B/INCENP protein kinase inhibitory activities in substrate phosphorylation assays (no data).			
IT 1089653-65-5P 1089653-66-6P				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of substituted 2-[(3-pyridylamino)-2-pyrimidinyl]anthranilamides as Aurora kinase inhibitors)			
RN 1089653-65-5 CAPLUS				
CN	Benzamide, 2-[(5-chloro-2-[[5-[(4-methyl-1-piperazinyl)methyl]-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)			



RN 1089653-66-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-[(dimethylamino)methyl]-1-methyl-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:158647 CAPLUS

DN 142:261547

TI Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

IN Garcia-echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya, Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro; Steensma, Ruo; Chopiuk, Greg; Jiang, Jiqing; Wan, Yongqin; Ding, Qiang; Zhang, Qiong; Gray, Nathanael Schiander; Karanewsky, Donald

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; IRM LLC

SO PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005016894	A1	20050224	WO 2004-EP9099	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004264382	A1	20050224	AU 2004-264382	20040813
CA 2533320	A1	20060224	CA 2004-2533320	20040813
EP 1660458	A1	20060531	EP 2004-764093	20040813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1832929	A	20060913	CN 2004-80022725	20040813
BR 2004013616	A	20061017	BR 2004-13616	20040813
JP 2007502260	T	20070208	JP 2006-522998	20040813
SG 145749	A1	20080929	SG 2008-6063	20040813
RU 2395500	C2	20100727	RU 2006-107785	20040813
KR 2006039938	A	20060509	KR 2006-7003056	20060214
KR 904570	B1	20090625		
MX 2006001759	A	20060512	MX 2006-1759	20060214
IN 2006CN00553	A	20070706	IN 2006-CN553	20060214
IN 240560	A1	20100528		
NO 2006001214	A	20060515	NO 2006-1214	20060315
US 20080132504	A1	20080605	US 2006-568367	20060818
AU 2008229685	A1	20081030	AU 2008-229685	20080929
PRAI GB 2003-19227	A	20030815		
GB 2003-22370	A	20030924		
AU 2004-264382	A3	20040813		
WO 2004-EP9099	W	20040813		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:261547; MARPAT 142:261547

AB The title compds. I [R = aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R0-R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, etc.], useful for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition

of FAK and/or ALK and/or ZAP-70 and/or IGF-1R, were prepared and formulated. E.g., a 2-step synthesis of II, starting from 2,4-dichloro-5-nitropyrimidine and 2-amino-N-methylbenzenesulfonamide, was given. The compds. I have IC₅₀ values in the range of 10 nM to 2 µM in cell-free ZAP-70 kinase assay.


IT 845815-23-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 845815-23-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(1,3-dimethyl-1H-pyrazol-5-yl)-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/568,367 (RCE)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.12

204.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.70

-1.70

STN INTERNATIONAL LOGOFF AT 17:02:05 ON 20 SEP 2010